[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Spugnini EP, Dotsinsky I, Mudrov N, Bufalini M, Giannini G, Citro G, Feroce F, Baldi A: Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog. In Vivo; 2008 Jan-Feb;22(1):47-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog.
  • Canine anal sac gland carcinoma (ASGC) is a frequently described neoplasm that is highly aggressive and can frequently lead to metastatic spread.
  • In this paper, we describe the successful treatment of an incompletely excised ASGC by using cisplatin selectively driven within the tumor cells by trains of biphasic pulses.
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Anal Sacs / drug effects. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Dog Diseases / drug therapy. Electrochemotherapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease-Free Survival. Dogs. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396781.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Venclauskas L, Saladzinskas Z, Tamelis A, Pranys D, Pavalkis D: Mucinous adenocarcinoma arising in an anorectal fistula. Medicina (Kaunas); 2009;45(4):286-90
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous adenocarcinoma in association with chronic anal fistula is a rare case in clinical practice.
  • The aim of this article was to report a rare case of anal gland mucinous adenocarcinoma in a patient who was treated in the Hospital of Kaunas University of Medicine.
  • Endoanal ultrasound findings showed soft tissue induration at the site of anorectal fistula, no tumor in the rectum wall.
  • Histological examination after abdominoperineal resection revealed anal duct mucinous adenocarcinoma pT2 N0 L0 V0 R0, G2.
  • [MeSH-major] Adenocarcinoma, Mucinous. Anus Neoplasms. Rectal Fistula / complications
  • [MeSH-minor] Abscess / complications. Aged. Anal Canal / pathology. Humans. Male. Neoplasm Staging. Perineum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19423959.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


3. MacNeill KN, Riddell RH, Ghazarian D: Perianal apocrine adenocarcinoma arising in a benign apocrine adenoma; first case report and review of the literature. J Clin Pathol; 2005 Feb;58(2):217-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for apocrine adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal apocrine adenocarcinoma arising in a benign apocrine adenoma; first case report and review of the literature.
  • Benign apocrine lesions have been described in the anogenital region, although according to the World Health Organisation convincing examples of anal apocrine adenocarcinomas have not been published.
  • This report describes the case of an invasive apocrine adenocarcinoma arising in a benign adenoma in the perianal region of a 45 year old woman.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Immunohistochemistry / methods. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for apocrine adenocarcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):829-32 [10690173.001]
  • [Cites] J Am Acad Dermatol. 2001 Nov;45(5):755-9 [11606929.001]
  • [Cites] J Am Acad Dermatol. 1980 Apr;2(4):322-6 [7364989.001]
  • [Cites] Arch Dermatol. 1980 Sep;116(9):1051-3 [7416759.001]
  • [Cites] Am J Clin Pathol. 1962 Feb;37:182-95 [14472046.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):375-81 [7678545.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):832-6 [8037297.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):75-84 [9426521.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):786-93 [10463481.001]
  • [Cites] Arch Pathol Lab Med. 1991 Dec;115(12):1249-54 [1662944.001]
  • (PMID = 15677547.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 12
  • [Other-IDs] NLM/ PMC1770559
  •  go-up   go-down


Advertisement
4. Parry NM: Anal sac gland carcinoma in a cat. Vet Pathol; 2006 Nov;43(6):1008-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in a cat.
  • A perianal mass in a 15-year-old domestic shorthair cat with a history of a firm, painful swelling in the left ventrolateral perianal region was surgically excised and submitted for light microscopic evaluation.
  • Histologically, this was a poorly demarcated, unencapsulated, multilobulated neoplasm that invaded surrounding perirectal skeletal muscle bundles.
  • These microscopic features are consistent with anal sac gland carcinoma.
  • This is the second report of this neoplasm in a cat.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Carcinoma / veterinary. Cat Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099161.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. España L, Martín B, Aragüés R, Chiva C, Oliva B, Andreu D, Sierra A: Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis. Am J Pathol; 2005 Oct;167(4):1125-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 435/Bcl-x(L) or 435/Neo human breast cancer cells were injected into the inguinal mammary gland of nude mice, and tumors, metastases in lymph node, lung, and bone, and bloodstream surviving cells were examined.
  • In conclusion, Bcl-x(L) mediates a phenotype in which redox pathways and glycolysis are coupled to protect breast cancer metastatic cells during transit from the primary tumor to the metastatic state.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / metabolism. Carcinoma / blood. Carcinoma / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Bone Neoplasms / genetics. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Bone and Bones. Cell Line, Tumor. Cell Survival. Computational Biology. Electrophoresis, Gel, Two-Dimensional. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lung. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Lymph Nodes. Lymphatic Metastasis / genetics. Lymphatic Metastasis / pathology. Mass Spectrometry. Mice. Mice, Nude. Models, Biological. Neoplasm Metastasis / genetics. Neoplasm Transplantation. Organ Specificity. Peptide Mapping. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Res. 2003 Jul;1(9):682-9 [12861054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4285-8 [10200254.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D449-51 [14681454.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):11-22 [14708024.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12589-94 [10535966.001]
  • [Cites] Nature. 1999 Nov 4;402(6757):86-90 [10573422.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):142-50 [10638981.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Mol Med Today. 2000 Apr;6(4):149-56 [10740253.001]
  • [Cites] Cell Death Differ. 2000 Apr;7(4):350-9 [10773819.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Cancer. 2000 Oct 25;90(5):286-91 [11038425.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):76-80 [11196201.001]
  • [Cites] Lab Invest. 2001 May;81(5):725-34 [11351044.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Breast Cancer Res Treat. 2001 Sep;69(1):39-51 [11759827.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(1):94-104 [11739725.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6649-54 [12011429.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19396-401 [11904290.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22718-24 [11956188.001]
  • [Cites] Curr Biol. 2002 Jun 25;12(12):1034-9 [12123579.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9830-5 [12118121.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):823 [12192390.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7611-8 [12400004.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):10-1 [12509774.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):258-61 [12519996.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):9-15 [12559171.001]
  • [Cites] Science. 2003 Apr 25;300(5619):650-3 [12714747.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):558-65 [12808061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42 [12808139.001]
  • [Cites] Cell. 2003 Jun 27;113(7):821-3 [12837240.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):332-7 [15029198.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1889-99 [15071501.001]
  • [Cites] Genome Res. 2004 Jun;14(6):1107-18 [15173116.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(1):33-44 [15377849.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1829-33 [8446596.001]
  • [Cites] J Biol Chem. 1993 Aug 15;268(23):17010-7 [8394326.001]
  • [Cites] Nat Med. 1995 Feb;1(2):149-53 [7585012.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Cancer J Sci Am. 1997 Jul-Aug;3(4):230-7 [9263629.001]
  • [Cites] Trends Biochem Sci. 1998 Sep;23(9):324-8 [9787636.001]
  • [Cites] J Pathol. 1999 Jan;187(1):91-4 [10341709.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):16-22 [15598930.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1565-79 [15855655.001]
  • [Cites] Adv Cancer Res. 2000;78:31-101 [10547668.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):80-5 [9890174.001]
  • [Cites] J Mass Spectrom. 1999 Feb;34(2):105-16 [10093212.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3808-14 [14506175.001]
  • (PMID = 16192647.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1603674
  •  go-up   go-down


6. Shoieb AM, Hanshaw DM: Anal sac gland carcinoma in 64 cats in the United kingdom (1995-2007). Vet Pathol; 2009 Jul;46(4):677-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in 64 cats in the United kingdom (1995-2007).
  • A retrospective study was performed to characterize 64 cases of anal sac gland carcinoma (ASGC) in cats.
  • Apocrine gland origin was confirmed in a subset of these tumors by immunohistochemistry and the use of the glandular cytokeratin antibody (CAM 5.2).
  • Anal sac gland carcinoma accounted for 0.5% of all feline skin neoplasms.
  • More than three quarters of the affected cats for which postsurgical outcome was known were euthanatized or died as a direct consequence of the neoplasm, with a median survival of 3 months.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Cat Diseases / epidemiology. Cat Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276061.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Riaz M, Elstrodt F, Hollestelle A, Dehghan A, Klijn JG, Schutte M: Low-risk susceptibility alleles in 40 human breast cancer cell lines. BMC Cancer; 2009;9:236
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our expression analyses suggest that a putative disease mechanism through gene expression modulation is not operative in breast cancer cell lines.
  • [MeSH-major] Alleles. Breast Neoplasms / diagnosis. Breast Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Exons. Gene Expression Profiling. Genes, Neoplasm. Genetic Predisposition to Disease. Genotype. Humans. Oligonucleotide Array Sequence Analysis. Phenotype. Polymorphism, Single Nucleotide. Reverse Transcriptase Polymerase Chain Reaction. Risk

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Res. 2004 Nov;2(11):643-52 [15561780.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):41-5 [16397213.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):873-5 [16832357.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jul;9(3):221-36 [15557796.001]
  • [Cites] Int J Cancer. 1995 Apr 10;61(2):170-6 [7705943.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):273-80 [1380281.001]
  • [Cites] Oncogene. 1991 Apr;6(4):659-63 [1851551.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1175-82 [15122511.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2289-92 [14676808.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1117-30 [12677558.001]
  • [Cites] Am J Hum Genet. 2002 Aug;71(2):432-8 [12094328.001]
  • [Cites] Nat Genet. 2002 May;31(1):55-9 [11967536.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):229-34 [11564899.001]
  • [Cites] Breast Cancer Res. 2000;2(3):191-6 [11250709.001]
  • [Cites] Nat Genet. 2006 Nov;38(11):1239-41 [17033622.001]
  • [Cites] PLoS One. 2008;3(8):e3007 [18688287.001]
  • [Cites] PLoS Biol. 2008 May 6;6(5):e108 [18462018.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4340-5 [18326623.001]
  • [Cites] Breast Cancer Res. 2007;9(6):113 [18036273.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):17-22 [18163131.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):984-8 [17618284.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):989-94 [17618283.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):954-6 [17618282.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):865-9 [17529974.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):165-7 [17200668.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):103-5 [17292821.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Nat Genet. 2007 May;39(5):638-44 [17401364.001]
  • [Cites] Nat Genet. 2007 May;39(5):631-7 [17401366.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):870-4 [17529973.001]
  • (PMID = 19607694.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3087328
  •  go-up   go-down


8. Wright ZM, Fryer JS, Calise DV, Oliveira FN: Carboplatin chemotherapy in a cat with a recurrent anal sac apocrine gland adenocarcinoma. J Am Anim Hosp Assoc; 2010 Jan-Feb;46(1):66-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin chemotherapy in a cat with a recurrent anal sac apocrine gland adenocarcinoma.
  • An 8-year-old, castrated male, domestic shorthaired cat was presented for evaluation of a perianal mass.
  • The mass was incompletely excised, and histological assessment resulted in a diagnosis of anal sac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / veterinary. Anal Gland Neoplasms / drug therapy. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Cat Diseases / drug therapy
  • [MeSH-minor] Anal Sacs / pathology. Animals. Cats. Fatal Outcome. Lung Neoplasms / secondary. Lung Neoplasms / veterinary. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / veterinary

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20045840.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


9. Hobson HP, Brown MR, Rogers KS: Surgery of metastatic anal sac adenocarcinoma in five dogs. Vet Surg; 2006 Apr;35(3):267-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery of metastatic anal sac adenocarcinoma in five dogs.
  • OBJECTIVE: To identify survival and morbidity information after surgery for metastases from apocrine gland anal sac adenocarcinomas (AGACA).
  • CONCLUSION: Dogs with anal sac adenocarcinoma metastases to the iliac lymph nodes can experience long-term survival after surgical excision of the metastatic lesion.
  • CLINICAL RELEVANCE: Lymphadenectomy may afford long-term survival to patients with metastatic anal sac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / surgery. Anal Sacs. Dog Diseases / surgery
  • [MeSH-minor] Animals. Dogs. Female. Lymph Node Excision / veterinary. Lymphatic Metastasis. Male. Neoplasm Metastasis. Postoperative Complications / veterinary. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Texas / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Compend Contin Educ Vet. 2008 Feb;30(2):69, 72 [23713167.001]
  • (PMID = 16635006.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Emms SG: Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J; 2005 Jun;83(6):340-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.
  • A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy.
  • Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma.
  • Two of the 19 dogs had bilateral anal sac adenocarcinomas.
  • Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy.
  • Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan.
  • Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases.
  • The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months.
  • This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Sacs. Dog Diseases / epidemiology
  • [MeSH-minor] Adenocarcinoma / veterinary. Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cystadenoma, Papillary / veterinary. Dogs. Female. Male. Melanoma / veterinary. Neoplasm Metastasis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Victoria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986909.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Wakatsuki K, Oeda Y, Isono T, Yoshioka S, Nukui Y, Yamazaki K, Nabeshima S, Miyazaki M: Adenocarcinoma of the rectosigmoid colon seeding into pre-existing anal fistula. Hepatogastroenterology; 2008 May-Jun;55(84):952-5
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the rectosigmoid colon seeding into pre-existing anal fistula.
  • This paper reports a rare case of rectosigmoid colon carcinoma metastasizing to anal fistula.
  • Two years and 3 months later, a subcutaneous tumor was found at the external opening of fistula.
  • Trans perineal tumor excision plus fistulectomy was performed.
  • Pathology revealed that the colon cancer and the perianal tumor were both moderately differentiated adenocarcinoma.
  • Many reports support the concept of tumor cell implantation in mucosa that have been altered or denuded by various factors.
  • Sixteen reports could be found of implantation metastasis of colorectal cancer into anal fistula.
  • In diagnosis, it is important to differentiate implantation of colorectal cancer in anal fistula from primary anal fistular adenocarcinoma.
  • The histology of the perianal tumor in this patient closely resembles the tumor of the colon.
  • Furthermore, immunohistochemistry for cytokeratins 7 and 20 was performed on tissues to distinguish colorectal adenocarcinoma from anal gland carcinoma.
  • Both colorectal cancer and perianal tumor showed CK7-/CK20+.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Neoplasm Seeding. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Colon, Sigmoid / pathology. Colon, Sigmoid / surgery. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705305.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Nakata M, Miwa Y, Nakayama H, Sakai T, Sasaki N: Localised radiotherapy for a ferret with possible anal sac apocrine adenocarcinoma. J Small Anim Pract; 2008 Sep;49(9):476-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised radiotherapy for a ferret with possible anal sac apocrine adenocarcinoma.
  • A seven-year-old, neutered male ferret was referred to our hospital with two perianal masses (2.4x3.0 and 2.4x3.5 cm, respectively) that had recurred after initial surgical excision.
  • On histopathology, the masses were diagnosed as apocrine adenocarcinoma possibly of anal gland origin based on tumour location.
  • Cytology of a sample of the pleural effusion suggested mesothelioma, and no obvious pulmonary metastasis of anal sac adenocarcinoma were identified on thoracic radiography.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / radiotherapy. Anal Sacs. Ferrets
  • [MeSH-minor] Animals. Fatal Outcome. Male. Mesothelioma / radiography. Mesothelioma / surgery. Mesothelioma / veterinary. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / veterinary. Neoplasms, Second Primary / radiography. Neoplasms, Second Primary / surgery. Neoplasms, Second Primary / veterinary. Pleural Effusion / etiology. Pleural Effusion / radiography. Pleural Effusion / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631226.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Ganguly A, Wolfe LG: Canine perianal gland carcinoma-associated antigens defined by monoclonal antibodies. Hybridoma (Larchmt); 2006 Feb;25(1):10-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine perianal gland carcinoma-associated antigens defined by monoclonal antibodies.
  • This study was conducted to distinguish canine perianal gland carcinomas from adenomas using monoclonal antibodies (MAbs).
  • To address this histopathological confusion, two perianal gland carcinoma-associated antigens were defined by mouse MAbs 4A9 and 1A10.
  • These MAbs, generated against a canine mammary carcinoma cell line, reacted strongly with perianal gland carcinoma in preliminary screening and therefore were selected for further investigation.
  • Cellular expression of antigens was examined by indirect immunoperoxidase (IP) assay using MAbs 4A9 and 1A10 against formalin-fixed, paraffin-embedded sections of normal and tumor tissue.
  • Of 25 perianal gland carcinomas, 4A9 antigen was expressed in 100% and 1A10 antigen in 84%.
  • In contrast, perianal gland adenomas were negative for both antigens, and little or no reactivity was detected with normal perianal glands.
  • With eight perianal gland tumors, diagnosis of carcinoma versus adenoma was histologically equivocal, while IP assays consistently revealed focal expression of the 4A9 and 1A10 antigens in these tumors, and the staining coincided with foci of anaplastic cells having a high mitotic index.
  • Results suggest that 4A9 and 1A10 antigens are markers of carcinoma and malignant transformation in canine perianal gland tumors, and can be very useful as diagnostic reagents where the identification of carcinoma versus adenoma requires additional clarification beyond routine histopathological examination.
  • [MeSH-major] Adenocarcinoma / veterinary. Adenoma / veterinary. Anal Gland Neoplasms / diagnosis. Antibodies, Monoclonal. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma / veterinary
  • [MeSH-minor] Animals. Cell Line, Tumor. Diagnosis, Differential. Dogs. Female. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475876.001).
  • [ISSN] 1554-0014
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Kirillov V, Stebenyaeva E, Demidchik E: Comparative morphometric analysis of thyrocytes in a primary tumor and regional metastases in papillary thyroid gland cancer. Anal Quant Cytol Histol; 2008 Aug;30(4):209-17
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative morphometric analysis of thyrocytes in a primary tumor and regional metastases in papillary thyroid gland cancer.
  • OBJECTIVE: To perform a comparative analysis of thyrocyte nuclei and the aggregability degree in tumor cells in the thyroid gland with papillary cancer and in cervical lymph nodes with metastases.
  • CONCLUSION: Malignant cells of the primary tumor have been shown to have evident quantitative features of nuclear atypia and a higher degree of aggregability compared with the norm.
  • The differences between the quantitative features of nuclei and aggregates in malignant cells of the primary tumor in the thyroid gland and its metastases in cervical lymph nodes were less pronounced.

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773739.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Huang ZM, Li HZ, Xiao H, Ji ZG: [Melanoma adrenal metastasis: report of 3 cases and literature review]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1123-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cases had a history of cutaneous melanoma and another one suffered previously from anal melanoma.
  • The disease-free interval to adrenal metastasis were 25, 37, 33 months respectively.
  • One received adrenalectomy via retroperitoneal laparoscopic approach while another patient with tumor thrombus in inferior vena cava underwent right adrenalectomy and extraction of tumor thrombus out of inferior vena cava in traditional open surgery.
  • CONCLUSION: Melanoma metastasis to adrenal gland is rare and it generally has a poor prognosis.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646432.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 8
  •  go-up   go-down


16. Sarathchandra SK, Lunn JA, Hunt GB: Ligation of the caudal mesenteric artery during resection and anastomosis of the colorectal junction for annular adenocarcinoma in two dogs. Aust Vet J; 2009 Sep;87(9):356-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The dogs were euthanased 8 and 10 months, respectively, after surgery because of clinical signs relating to metastatic disease.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / surgery. Dog Diseases / surgery. Mesenteric Arteries / surgery
  • [MeSH-minor] Anastomosis, Surgical / veterinary. Animals. Dogs. Female. Ligation / veterinary. Neoplasm Metastasis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703136.001).
  • [ISSN] 1751-0813
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 16
  •  go-up   go-down


17. Amir S, Margaryan NV, Odero-Marah V, Khalkhali-Ellis Z, Hendrix MJ: Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biol Ther; 2005 Apr;4(4):400-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maspin, a unique serine proteinase inhibitor (serpin), plays a key role in mammary gland development and is silenced during breast cancer progression.
  • Maspin has been shown to inhibit tumor cell motility and invasion in cell culture, as well as growth and metastasis in animal models.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):1-22 [9212216.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Blood. 1998 May 1;91(9):3300-7 [9558386.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5863-70 [10606224.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8676-82 [11751384.001]
  • [Cites] Med Res Rev. 2001 Mar;21(2):146-70 [11223863.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):400-5 [11196194.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):2018-24 [11064360.001]
  • [Cites] Gene Ther. 1998 Aug;5(8):1105-13 [10326034.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):617-23 [9935166.001]
  • [Cites] Nat Med. 2000 Feb;6(2):196-9 [10655109.001]
  • [Cites] Thromb Haemost. 1999 Sep;82 Suppl 1:19-22 [10695480.001]
  • [Cites] Nat Med. 2000 Apr;6(4):374-6 [10742136.001]
  • [Cites] Cancer Gene Ther. 2000 Feb;7(2):292-9 [10770639.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2775-83 [11023511.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1194-7 [12142372.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4478-83 [12154058.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7824-30 [12420219.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1411-7 [12707024.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4):398-403 [14508113.001]
  • [Cites] Anal Biochem. 1980 Feb;102(1):196-202 [7188842.001]
  • [Cites] Biochemistry. 1982 Dec 7;21(25):6410-5 [6891264.001]
  • [Cites] Cell. 1983 Dec;35(3 Pt 2):611-9 [6418388.001]
  • [Cites] Cancer Lett. 1987 Dec;38(1-2):137-47 [3690504.001]
  • [Cites] Blood. 1988 Jun;71(6):1703-6 [3259442.001]
  • [Cites] J Biol Chem. 1988 Aug 15;263(23):11189-95 [2969891.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(24):9533-7 [3200838.001]
  • [Cites] J Biol Chem. 1990 Jun 15;265(17):9904-8 [2161846.001]
  • [Cites] J Clin Invest. 1991 Oct;88(4):1067-72 [1833420.001]
  • [Cites] Physiol Rev. 1993 Jan;73(1):161-95 [8419965.001]
  • [Cites] J Biol Chem. 1993 Mar 5;268(7):4806-13 [8444857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5021-5 [8389464.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3109-17 [8391387.001]
  • [Cites] Science. 1994 Jan 28;263(5146):526-9 [8290962.001]
  • [Cites] Cancer Metastasis Rev. 1994 Jun;13(2):139-68 [7923547.001]
  • [Cites] J Biol Chem. 1994 Dec 9;269(49):30988-93 [7983035.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 1):51-64 [8814994.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11669-74 [8876194.001]
  • [Cites] Clin Exp Metastasis. 1997 Jan;15(1):19-25 [9009102.001]
  • [Cites] Biol Chem. 1997 Mar-Apr;378(3-4):231-7 [9165076.001]
  • [CommentIn] Cancer Biol Ther. 2005 Sep;4(9):1033-5 [16123583.001]
  • (PMID = 15846059.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075681; United States / NCI NIH HHS / CA / R01 CA075681-10; United States / NCI NIH HHS / CA / CA 75681
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 0 / SERPIN-B5; 0 / Serpins; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS323567; NLM/ PMC3175738
  •  go-up   go-down


18. Lee SE, Jeon EJ, Oh JH, Shim KH, Lee J, Kim EH, Choi SW, Min KO: [A case of advanced gastric cancer with perianal skin metastasis]. Korean J Gastroenterol; 2008 Jan;51(1):40-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with perianal skin metastasis].
  • The most common metastatic sites of gastric cancer are liver, lung, bone and adrenal gland.
  • We herein report a case of advanced gastric cancer with perianal skin metastasis in a 70-year-old male.
  • He had one painless nodule on perianal skin area, biopsy of that lesion showed a feature of poorly differentiated adenocarcinoma clinically from the stomach.
  • We suspected that the perianal lesion was originated from gastric cancer.
  • [MeSH-major] Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal. Humans. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349561.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


19. Yan H, Blackburn AC, McLary SC, Tao L, Roberts AL, Xavier EA, Dickinson ES, Seo JH, Arenas RB, Otis CN, Cao QJ, Lawlor RG, Osborne BA, Kittrell FS, Medina D, Jerry DJ: Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. Am J Pathol; 2010 Mar;176(3):1421-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammary gland proliferation rates were similar in both BALB/c-Trp53+/- mice and wild-type controls.
  • Expression of biomarkers was retained when tumor fragments were transplanted to syngeneic hosts.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2004 Mar;34(3):726-34 [14991602.001]
  • [Cites] Trends Genet. 2004 Jun;20(6):235-43 [15145576.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3525-32 [15150107.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5140-7 [15289317.001]
  • [Cites] Cell. 1987 May 22;49(4):465-75 [3032456.001]
  • [Cites] Cell Growth Differ. 1990 Apr;1(4):161-70 [1707299.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2277-84 [1685017.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1269-74 [7731676.001]
  • [Cites] Anal Biochem. 1995 Mar 20;226(1):91-9 [7785785.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] Oncogene. 1997 Feb 20;14(7):865-71 [9047394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9648-53 [9275177.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1573-81 [9771927.001]
  • [Cites] Oncogene. 1998 Nov 5;17(18):2305-12 [9811461.001]
  • [Cites] J Pathol. 1999 Jul;188(3):237-44 [10419589.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):165-71 [15619621.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8166-73 [16166291.001]
  • [Cites] Cell Cycle. 2005 Dec;4(12):1808-16 [16294019.001]
  • [Cites] Development. 2006 Jan;133(2):363-9 [16368933.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5104-10 [16707433.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):1003-16 [16543940.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3463-70 [16449974.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5906-11 [16998505.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23 [17202265.001]
  • [Cites] Cell Res. 2007 Jan;17(1):42-9 [17211451.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1736-42 [17032926.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):103-5 [17292821.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5842-52 [17179143.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):2030-41 [17525270.001]
  • [Cites] Trends Cell Biol. 2007 Jun;17(6):286-91 [17481900.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6 [17626182.001]
  • [Cites] PLoS Biol. 2007 Aug;5(8):e201 [17676974.001]
  • [Cites] Stem Cell Rev. 2007 Jun;3(2):169-75 [17873349.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] Nat Cell Biol. 2008 Jun;10(6):676-87 [18454141.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4674-82 [18559513.001]
  • [Cites] Cell. 2008 Jul 11;134(1):62-73 [18614011.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R43 [18471300.001]
  • [Cites] Neurobiol Aging. 2009 Mar;30(3):483-97 [17850928.001]
  • [Cites] Nature. 2009 Jul 23;460(7254):529-33 [19626115.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1052-8 [10713689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3444-9 [10716706.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1996 Jan;1(1):5-19 [10887477.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):2151-9 [11106587.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83-7 [11219776.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4621-8 [11498785.001]
  • [Cites] Nat Genet. 2002 May;31(1):55-9 [11967536.001]
  • [Cites] FASEB J. 2002 Jun;16(8):881-3 [11967232.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):289-98 [12086865.001]
  • [Cites] Mutat Res. 2003 Jan 28;522(1-2):69-83 [12517413.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):292-300 [12619115.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6140-3 [14559792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • (PMID = 20110418.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES015739; United States / NCI NIH HHS / CA / R01-CA105452; United States / NCI NIH HHS / CA / R01 CA095164; United States / NCI NIH HHS / CA / R01 CA105452; United States / NCI NIH HHS / CA / R01-CA095164; United States / NIEHS NIH HHS / ES / R01-ES015739
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Notch; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2832161
  •  go-up   go-down


20. Vogl TJ, Zangos S, Eichler K, Balzer JO, Jacob U, Keilhauer R, Bauer RW: [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases]. Rofo; 2007 Nov;179(11):1174-80
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Transarterielle Chemoperfusion des Beckens--Ergebnisse bei symptomatischen Rezidivtumoren und Lymphknotenmetastasen.
  • PURPOSE: To evaluate local transarterial chemoperfusion (TACP) of therapy-resistant, locally recurrent malignant tumors and lymph node metastases in the pelvis with respect to clinical response, tumor response and survival.
  • Depending on the tumor location and vascularization, a fluoroscopy catheter was placed either in the abdominal aorta or internal pelvic artery.
  • The tumor size was measured using CT or MRI.
  • The radiological response was classified according to RECIST (Response Evaluation Criteria In Solid Tumors) as "complete response" (CR), "partial response" (PR), "stable disease" (SD) and "progressive disease" (PD).
  • The clinical response was classified as "response (clinical)" if the symptoms improved distinctly, "stable disease (clinical)" if complaints were stabilized, and "progression (clinical)" if symptoms deteriorated or new symptoms appeared.
  • In the case of clinical and radiological progression, therapy was stopped and the patient was referred to the hospital's tumor board.
  • Tumor-related pain, bleeding, restricted mobility of the lower extremities, incontinence, urinary tract obstruction, and constipation were reduced in 9/17, 5/6, 3/3, 1/3, 2/5, and 1/3 of cases (clinical response rate: 54%).
  • Radiologically, 4/24 (17%) patients showed PR, 12/24 (50%) SD, and 8/24 (34%) PD (tumor control (PR+SD): 67% of cases).
  • Tumor response (median survival since first TACP) was as follows: colorectal: 2 PR, 7 SD, 2 PD (11.5 months), ovarian: 1 SD, 2 PD (8.5 mon), cervical: 1 PR, 1 SD (6 mon), breast: 2 SD (6 mon), gastric: 1 PD (11 mon), adrenal gland: 1 PD (12 mon), anal: 1 PD (10 mon), prostate: 1 PD (20 mon), Gartner's duct: 1 PR (20 mon), renal cell carcinoma: 1 SD (10 mon).
  • CONCLUSION: Since tumor-related complaints were improved in 54% of the cases and control of tumor growth (PR+SD) was achieved in 67% of the cases, TACP for recurrent pelvic malignancies should be considered as a palliative oncological treatment option.
  • [MeSH-major] Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arteries. Drug Resistance, Neoplasm. Female. Humans. Injections, Intra-Arterial / adverse effects. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Perfusion / adverse effects. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805998.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


21. Spugnini EP, Dotsinsky I, Mudrov N, Citro G, D'Avino A, Baldi A: Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma. J Exp Clin Cancer Res; 2008;27:58
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma.
  • Sticker's sarcoma (also known as transmissible venereal tumor) is a horizontally transmitted neoplasm of the dog, that is passed with coitus.
  • It is a locally aggressive tumor with a low tendency to metastatic spread.
  • The most common locations are the genitals, the nose, the perianal area.
  • In this article we describe the outcome of a small cohort of canine patients, with chemotherapy resistant transmissible venereal tumor (TVT), treated with bleomycin selectively driven by trains of biphasic pulses (electrochemotherapy).
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Dog Diseases / drug therapy. Electrochemotherapy / veterinary. Sarcoma / veterinary. Venereal Tumors, Veterinary / drug therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease Models, Animal. Dogs. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2008;40(2):159-63 [17977058.001]
  • [Cites] J Transl Med. 2007;5:48 [17910745.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):483-7 [18365542.001]
  • [Cites] In Vivo. 2008 Jan-Feb;22(1):47-9 [18396781.001]
  • [Cites] In Vivo. 2008 Jan-Feb;22(1):51-3 [18396782.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jul;57(7):1091-104 [18259750.001]
  • [Cites] Vet J. 2008 Nov;178(2):291-3 [17910926.001]
  • [Cites] Vet J. 2009 Jan;179(1):117-20 [17904882.001]
  • [Cites] Vet Immunol Immunopathol. 2003 May 12;92(3-4):149-62 [12730015.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1508-14 [14734728.001]
  • [Cites] Radiology. 2004 Mar;230(3):761-7 [14990840.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4):571-80 [15053299.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(3):214-8 [1733554.001]
  • [Cites] IEEE Eng Med Biol Mag. 1999 Jan-Feb;18(1):62-6 [9934602.001]
  • [Cites] J Vet Med A Physiol Pathol Clin Med. 2005 Sep;52(7):366-70 [16109105.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Jun;24(2):245-54 [16110758.001]
  • [Cites] Melanoma Res. 2006 Feb;16(1):23-7 [16432452.001]
  • [Cites] J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):351-8 [16517782.001]
  • [Cites] Cell. 2006 Aug 11;126(3):445-7 [16901777.001]
  • [Cites] Cell. 2006 Aug 11;126(3):477-87 [16901782.001]
  • [Cites] Vet Rec. 2006 Oct 28;159(18):598-600 [17071674.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):375-81 [16807731.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4585-9 [17201181.001]
  • [Cites] Bioelectrochemistry. 2007 May;70(2):283-6 [17150416.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Sep;26(3):343-6 [17987793.001]
  • [Cites] In Vivo. 2007 Sep-Oct;21(5):819-22 [18019417.001]
  • [Cites] In Vivo. 2007 Sep-Oct;21(5):897-9 [18019432.001]
  • [Cites] Vet Rec. 2008 Feb 9;162(6):186-8 [18263920.001]
  • (PMID = 18980687.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  • [Other-IDs] NLM/ PMC2596090
  •  go-up   go-down


22. Bollito E, Terrone C, Volpe A, Porpiglia F, Cracco C, Poggio M, Grande S, Righi L, Bellina M, Papotti M, Scarpa RM: Changes in prostate cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience. Anal Quant Cytol Histol; 2008 Jun;30(3):152-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median tumor volume decreased significantly over time (p<0.001).
  • PSA value has progressively lost correlation with prostate cancer volume and today correlates only with prostate gland volume.
  • In early prostate cancer, PSA level no longer correlates with tumor volume.


23. Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Klein A, Cameron JL, Olino K, Schulick R, Winter J, Vogelstein B, Velculescu VE, Kinzler KW, Hruban RH: Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res; 2009 Apr 15;69(8):3681-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When adjusted for age and gender, analyses of the discovery screen revealed significantly more nonsynonymous mutations in the carcinomas obtained from ever smokers (mean, 53.1 mutations per tumor; SD, 27.9) than in the carcinomas obtained from never smokers (mean, 38.5; SD, 11.1; P = 0.04).
  • No differences were observed in mutations in carcinomas from the head versus tail of the gland.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3155-9 [10866304.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • [Cites] JAMA. 2001 Aug 22-29;286(8):921-9 [11509056.001]
  • [Cites] Cancer J. 2001 Jul-Aug;7(4):251-8 [11561601.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1525-30 [11745231.001]
  • [Cites] Chem Res Toxicol. 2002 May;15(5):677-85 [12018989.001]
  • [Cites] Cancer Causes Control. 2002 Apr;13(3):249-54 [12020106.001]
  • [Cites] Oncogene. 2002 Oct 21;21(48):7435-51 [12379884.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1343-53 [12468956.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Mar;130(3):303-6 [15023836.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1024-7 [2072410.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):213-20 [8434702.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):432-8 [8319174.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Am J Public Health. 1994 Jul;84(7):1086-93 [8017530.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]
  • [Cites] N Engl J Med. 1995 Mar 16;332(11):712-7 [7854378.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Semin Oncol. 1996 Apr;23(2):241-50 [8623060.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):63-71 [8690527.001]
  • [Cites] Science. 1996 Oct 18;274(5286):430-2 [8832894.001]
  • [Cites] Arch Intern Med. 1996 Oct 28;156(19):2255-60 [8885826.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):326-32 [10023699.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1830-7 [10468306.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5076-83 [15958551.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):370-5 [15906354.001]
  • [Cites] Risk Anal. 2006 Aug;26(4):881-92 [16948683.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1825-8 [17035388.001]
  • [Cites] Pancreas. 2007 Jan;34(1):55-62 [17198183.001]
  • [Cites] Pancreas. 2007 Aug;35(2):135-41 [17632319.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1894-7 [17855711.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):155-64 [17893872.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Am J Gastroenterol. 2007 Dec;102(12):2696-707 [17764494.001]
  • [Cites] Int J Gastrointest Cancer. 2006;37(4):139-45 [18049799.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):287-95 [18271927.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4283-8 [18337506.001]
  • [Cites] Langenbecks Arch Surg. 2008 Jul;393(4):535-45 [18193270.001]
  • [Cites] Langenbecks Arch Surg. 2008 Jul;393(4):581-8 [18193450.001]
  • [Cites] Cancer Causes Control. 2000 Dec;11(10):915-23 [11142526.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16224-9 [18852474.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Aust N Z J Public Health. 1999 Dec;23(6):654-6 [10641361.001]
  • (PMID = 19351817.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / P50 CA062924-160011; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / P50 CA062924-08S30011; United States / NCI NIH HHS / CA / P50 CA062924-090011; United States / NCI NIH HHS / CA / CA062924-08S30011; United States / NCI NIH HHS / CA / R01 CA039416; United States / NCI NIH HHS / CA / CA062924-090011; United States / NCI NIH HHS / CA / CA062924-160011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS98299; NLM/ PMC2669837
  •  go-up   go-down


24. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP: Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics; 2009 Apr;8(4):661-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Ascites / metabolism. Biomarkers, Tumor / analysis. Ovarian Neoplasms / metabolism. Proteome / analysis
  • [MeSH-minor] Chemical Fractionation. Chromatography, Gel. Chromatography, Liquid. Female. Humans. Kallikreins / analysis. Mass Spectrometry. Neoplasm Proteins / analysis. Neoplasm Proteins / chemistry. Protein Transport. Subcellular Fractions / metabolism. Ultrafiltration

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2008 Jan;7(1):339-51 [18076136.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Cell Biochem Biophys. 2007;49(3):182-95 [17952643.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):569-72 [10769727.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:45-50 [10804091.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):369-75 [11018688.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3903-6 [11268474.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7293-300 [11704858.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1353-7 [11762804.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1917-24 [12414537.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):807-11 [12591730.001]
  • [Cites] Tumour Biol. 2002 Sep-Oct;23(5):303-14 [12595747.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):433-40 [12882527.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Clin Chem. 2004 Apr;50(4):709-16 [14764643.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):999-1011 [15194082.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Jul;31(7):1003-7 [15272576.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1981-5 [15274388.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Neoplasma. 1979;26(6):737-43 [44348.001]
  • [Cites] Tokai J Exp Clin Med. 1982 May;7(3):325-9 [6896935.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1985 Jun;19(6):354-6 [4018373.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] PLoS One. 2008;3(6):e2425 [18560578.001]
  • [Cites] J Transl Med. 2008;6:41 [18652693.001]
  • [Cites] Cancer Treat Rev. 1995 May;21(3):215-45 [7656266.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2799-804 [8669868.001]
  • [Cites] Biochem Pharmacol. 1997 Sep 1;54(5):541-4 [9337069.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1843-9 [9581823.001]
  • [Cites] J Biomol Tech. 2004 Dec;15(4):238-48 [15585820.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):837-45 [15952730.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2885-9 [16080542.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3292-303 [16052620.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3304-13 [16052628.001]
  • [Cites] Proteomics. 2005 Oct;5(15):4034-45 [16152657.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):267-77 [16061277.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):316-9 [16240401.001]
  • [Cites] BMC Cancer. 2005;5:133 [16225703.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4625-36 [16220531.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4589-96 [16237736.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] Genome Biol. 2006;7(5):R40 [16709260.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66 [17255266.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):435-42 [17023034.001]
  • [Cites] Genome Biol. 2006;7(8):R72 [16901338.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] J Proteome Res. 2007 May;6(5):1728-34 [17397210.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2859-65 [17567164.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8 [17671125.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2753-8 [17695443.001]
  • [Cites] Mol Cell Proteomics. 2007 Aug;6(8):1406-15 [17495049.001]
  • [Cites] J Cell Biochem. 1990 May;43(1):43-57 [2189881.001]
  • [Cites] J Clin Invest. 1993 Nov;92(5):2160-7 [8227331.001]
  • [Cites] Tumour Biol. 1993;14(6):360-8 [8265982.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1997-2011 [17656355.001]
  • [Cites] J Proteome Res. 2007 Dec;6(12):4549-55 [17970587.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7370-9 [18094419.001]
  • (PMID = 19047685.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proteome; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2667349
  •  go-up   go-down


25. Stuelten CH, Busch JI, Tang B, Flanders KC, Oshima A, Sutton E, Karpova TS, Roberts AB, Wakefield LM, Niederhuber JE: Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One; 2010;5(3):e9832
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer.
  • When a cancer cell metastasizes, it first will be exposed to cancer associated fibroblasts in the immediate tumor microenvironment and then to normal fibroblasts as it traverses the underlying connective tissue towards the bloodstream.
  • The interaction of tumor cells with stromal fibroblasts influences tumor biology by mechanisms that are not yet fully understood.
  • Transient treatment of MCF10CA1a cells with CoCM in vitro accelerated tumor growth at orthotopic sites in vivo, and resulted in an expanded pattern of metastatic engraftment.
  • The effects of CoCM on MCF10CA1a cells were dependent on small amounts of active TGF-beta1 secreted by fibroblasts under the influence of the tumor cells, and required intact ALK5-, p38-, and JNK signaling in the tumor cells.
  • In conclusion, these results demonstrate that transient interactions between tumor cells and normal fibroblasts can modify the acellular component of the local microenvironment such that it induces long-lasting increases in tumorigenicity and alters the metastatic pattern of the cancer cells in vivo.
  • [MeSH-major] Breast Neoplasms / pathology. Fibroblasts / cytology. Neoplasms / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement. Coculture Techniques. Culture Media, Conditioned / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Models, Biological. Neoplasm Metastasis. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):329-41 [15970443.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5053-68 [15856015.001]
  • [Cites] Cell Cycle. 2005 Aug;4(8):1022-5 [16082203.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7624-9 [16007121.001]
  • [Cites] Expert Opin Ther Targets. 2005 Dec;9(6):1217-33 [16300472.001]
  • [Cites] Cell Mol Life Sci. 2006 Feb;63(4):449-68 [16416030.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:383-8 [16869775.001]
  • [Cites] Immunol Invest. 2006;35(3-4):297-325 [16916756.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:287-309 [16824016.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4244-53 [17483336.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):851-61 [17486574.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):593-608 [17729308.001]
  • [Cites] Biotechniques. 2007 Sep;43(3):289-90, 292, 294 [17907571.001]
  • [Cites] Clin Transl Oncol. 2008 Jan;10(1):14-9 [18208788.001]
  • [Cites] Front Biosci. 2008;13:3975-85 [18508491.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7278-82 [18794114.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):415-32 [12882526.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1116-24 [14523048.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8284-92 [14678987.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):822-32 [14970860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4523-30 [15231662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7678-82 [2217201.001]
  • [Cites] Semin Cancer Biol. 1990 Apr;1(2):99-106 [2103492.001]
  • [Cites] EXS. 1993;65:301-10 [7678533.001]
  • [Cites] Endocrinology. 1994 Mar;134(3):1039-45 [8119140.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40 [7972041.001]
  • [Cites] Science. 1995 Dec 22;270(5244):2008-11 [8533096.001]
  • [Cites] Anal Biochem. 1997 Apr 5;247(1):45-51 [9126369.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78 [11252892.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):22-9 [11790550.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):331-9 [11832448.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1057-68 [11891202.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):859-67 [12373600.001]
  • [Cites] Cell. 2005 Feb 25;120(4):513-22 [15734683.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2143-53 [15855236.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5278-83 [15958574.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R402-10 [15987445.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):1197-205 [16002723.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • (PMID = 20352126.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2843748
  •  go-up   go-down


26. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S: Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res; 2007 Nov 1;67(21):10564-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth.
  • Pituitary tumor-transforming gene (Pttg) deletion results in pituitary hypoplasia, low pituitary cell proliferation rates, and rescue of pituitary tumor development in Rb(+/-) mice.
  • As cell proliferation assessed by bromodeoxyuridine incorporation was higher in Rb(+/-)Pttg(-/-)p21(-/-) relative to Rb(+/-)Pttg(-/-) pituitary glands, p21-dependent senescence provoked by Pttg deletion may underlie pituitary hypoplasia and decreased tumor development in Rb(+/-)Pttg(-/-) mice.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):125-6 [9744268.001]
  • [Cites] EMBO J. 1999 Jan 4;18(1):22-7 [9878046.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Mech Dev. 1999 Mar;81(1-2):23-35 [10330482.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):7011-9 [10490638.001]
  • [Cites] Oncogene. 1999 Sep 23;18(39):5473-6 [10498901.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51100-6 [15456744.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):25-36 [17189716.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Oncogene. 2001 Feb 22;20(8):962-71 [11314031.001]
  • [Cites] Cell. 2001 May 18;105(4):445-57 [11371342.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):748-53 [11698192.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Nat Cell Biol. 2000 Mar;2(3):148-55 [10707085.001]
  • [Cites] Pituitary. 1999 May;1(3-4):169-79 [11081195.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10305-9 [12124396.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Minerva Endocrinol. 2002 Dec;27(4):277-85 [12511850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):25-39, vi [12690977.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2814-21 [12767095.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):1998-2008 [15021887.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3296-307 [15021915.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):501-13 [15149599.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] J Cell Biol. 1997 Jan 13;136(1):1-4 [9026502.001]
  • (PMID = 17975001.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-09; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA75979; United States / NCI NIH HHS / CA / R01 CA075979-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Retinoblastoma Protein; 0 / Securin; 0 / Sp1 Transcription Factor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS121885; NLM/ PMC2770267
  •  go-up   go-down


27. Burger LL, Haisenleder DJ, Aylor KW, Marshall JC: Regulation of Lhb and Egr1 gene expression by GNRH pulses in rat pituitaries is both c-Jun N-terminal kinase (JNK)- and extracellular signal-regulated kinase (ERK)-dependent. Biol Reprod; 2009 Dec;81(6):1206-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of Lhb and Egr1 gene expression by GNRH pulses in rat pituitaries is both c-Jun N-terminal kinase (JNK)- and extracellular signal-regulated kinase (ERK)-dependent.
  • Pulsatile GNRH regulates the gonadotropin subunit genes in a differential manner, with faster frequencies favoring Lhb gene expression and slower frequencies favoring Fshb.
  • Early growth response 1 (EGR1) is critical for Lhb gene transcription.
  • We examined GNRH regulation of EGR1 and its two corepressors, Ngfi-A-binding proteins 1 and 2 (NAB1 and NAB2), both in vivo and in cultured rat pituitary cells.
  • In rats, fast GNRH pulses (every 30 min) stably induced Egr1 primary transcript (PT) and mRNA 2-fold (P < 0.05) for 1-24 h.
  • In contrast, slow GNRH pulses (every 240 min) increased Egr1 PT at 24 h (6-fold; P < 0.05) but increased Egr1 mRNA 4- to 5-fold between 4 and 24 h.
  • Both GNRH pulse frequencies increased EGR1 protein 3- to 4-fold.
  • In cultured rat pituitary cells, GNRH pulses (every 60 min) increased Egr1 (PT, 2.5- to 3-fold; mRNA, 1.5- to 2-fold; P < 0.05).
  • GNRH pulses had little effect on Nab1/2 PT/mRNAs either in vivo or in vitro.
  • We also examined specific intracellular signaling cascades activated by GNRH.
  • Inhibitors of mitogen-activated protein kinase 8/9 (MAPK8/9 [also known as JNK]; SP600125) and MAP Kinase Kinase 1 (MAP2K1 [also known as MEK1]; PD98059) either blunted or totally suppressed the GNRH induction of Lhb PT and Egr1 PT/mRNA, whereas the MAPK14 (also known as p38) inhibitor SB203580 did not.
  • In summary, pulsatile GNRH stimulates Egr1 gene expression and protein in vivo but not in a frequency-dependent manner.
  • Additionally, GNRH-induced Egr1 gene expression is mediated by MAPK8/9 and MAPK1/3, and both are critical for Lhb gene transcription.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Mol Med. 2006 Dec 31;38(6):677-85 [17202844.001]
  • [Cites] Mol Endocrinol. 2007 May;21(5):1175-91 [17299135.001]
  • [Cites] Mol Endocrinol. 2007 May;21(5):1216-33 [17327421.001]
  • [Cites] Biol Reprod. 2007 Dec;77(6):1073-80 [17699734.001]
  • [Cites] Biochem J. 2007 Dec 15;408(3):297-315 [17850214.001]
  • [Cites] Endocrinology. 2008 Jan;149(1):139-45 [17932215.001]
  • [Cites] J Biol Chem. 2008 May 2;283(18):12120-8 [18281687.001]
  • [Cites] Cell Biol Int. 2008 Jul;32(7):769-76 [18455449.001]
  • [Cites] Endocrinology. 2008 Nov;149(11):5577-91 [18653705.001]
  • [Cites] Biol Reprod. 2008 Nov;79(5):947-53 [18716286.001]
  • [Cites] J Cell Biochem. 2008 Dec 1;105(5):1267-78 [18814180.001]
  • [Cites] EMBO J. 2009 Jan 7;28(1):21-33 [19057511.001]
  • [Cites] Mol Endocrinol. 2009 Feb;23(2):237-50 [19095772.001]
  • [Cites] Mol Endocrinol. 2009 Jul;23(7):1092-101 [19372235.001]
  • [Cites] J Biol Chem. 1999 May 14;274(20):13870-6 [10318795.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1009-12 [10514380.001]
  • [Cites] J Appl Physiol (1985). 2004 Dec;97(6):2207-13 [15310743.001]
  • [Cites] Prog Neurobiol. 2004 Nov;74(4):183-211 [15556287.001]
  • [Cites] J Mol Endocrinol. 2004 Dec;33(3):559-84 [15591020.001]
  • [Cites] Eur J Neurosci. 2004 Dec;20(12):3371-7 [15610169.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9193-200 [10734055.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14182-9 [10799494.001]
  • [Cites] DNA Seq. 2000;10(6):429-32 [10826704.001]
  • [Cites] J Neuroendocrinol. 2000 Jul;12(7):671-6 [10849212.001]
  • [Cites] Mol Endocrinol. 2000 Aug;14(8):1235-45 [10935547.001]
  • [Cites] Endocrinology. 1994 Sep;135(3):876-80 [8070381.001]
  • [Cites] Endocrinology. 1995 May;136(5):1885-91 [7720634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6873-7 [7624335.001]
  • [Cites] J Neuroendocrinol. 1995 Oct;7(10):739-57 [8563717.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1265-71 [8625898.001]
  • [Cites] J Biol Chem. 1996 Jun 7;271(23):13530-6 [8662759.001]
  • [Cites] Science. 1996 Aug 30;273(5279):1219-21 [8703054.001]
  • [Cites] Mol Endocrinol. 1998 Jan;12(1):107-22 [9440815.001]
  • [Cites] Mol Biol Evol. 1998 Mar;15(3):284-92 [9501495.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1740-9 [9501095.001]
  • [Cites] Mol Endocrinol. 1998 Mar;12(3):451-7 [9514161.001]
  • [Cites] J Biol Chem. 1998 Jun 12;273(24):14712-20 [9614069.001]
  • [Cites] Endocrinology. 1998 Jul;139(7):3104-11 [9645682.001]
  • [Cites] J Clin Invest. 1998 Nov 15;102(10):1850-9 [9819371.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):106-16 [9892016.001]
  • [Cites] Endocrinology. 1999 Mar;140(3):1310-8 [10067858.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2567-76 [10082522.001]
  • [Cites] Mol Endocrinol. 1999 May;13(5):752-63 [10319325.001]
  • [Cites] Biol Reprod. 2005 Mar;72(3):523-9 [15509729.001]
  • [Cites] J Cell Physiol. 2005 Sep;204(3):964-74 [15799027.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1382-91 [15890690.001]
  • [Cites] Mol Endocrinol. 2005 Oct;19(10):2624-38 [15961508.001]
  • [Cites] Endocrinology. 2005 Dec;146(12):5503-13 [16141398.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):42785-93 [16260776.001]
  • [Cites] Biol Reprod. 2006 Jun;74(6):993-8 [16481592.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jun 27;252(1-2):184-90 [16682115.001]
  • [Cites] Endocrinology. 2001 Jan;142(1):139-46 [11145576.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 2001 Jun;129(2-3):525-32 [11399488.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2438-52 [11402339.001]
  • [Cites] Mol Endocrinol. 2002 Feb;16(2):221-33 [11818496.001]
  • [Cites] Endocrinology. 2002 Mar;143(3):1018-25 [11861527.001]
  • [Cites] Mol Endocrinol. 2002 Mar;16(3):419-34 [11875099.001]
  • [Cites] Mol Cell Endocrinol. 2002 Mar 28;189(1-2):85-96 [12039067.001]
  • [Cites] Endocrinology. 2002 Sep;143(9):3243-9 [12193535.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32099-108 [12050161.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 21;1592(2):163-7 [12379479.001]
  • [Cites] J Cell Physiol. 2002 Dec;193(3):287-92 [12384981.001]
  • [Cites] Endocrinology. 2003 Mar;144(3):839-49 [12586760.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5845-53 [12475986.001]
  • [Cites] Endocrinology. 2003 Jul;144(7):2768-74 [12810529.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):152-62 [14570911.001]
  • [Cites] J Mol Endocrinol. 2004 Feb;32(1):291-306 [14766009.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):83-94 [15225550.001]
  • [Cites] Mol Cell Endocrinol. 2004 Oct 15;225(1-2):29-36 [15451565.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Cell. 1988 Apr 8;53(1):37-43 [3127059.001]
  • [Cites] Endocr Rev. 1990 Feb;11(1):177-99 [2108012.001]
  • [Cites] Endocr Rev. 1990 May;11(2):326-53 [2194785.001]
  • [Cites] Mol Endocrinol. 1990 Dec;4(12):1943-55 [1707128.001]
  • [Cites] Cell Growth Differ. 1991 Jun;2(6):273-8 [2064996.001]
  • [Cites] Mol Cell Endocrinol. 1991 Sep;80(1-3):193-202 [1659545.001]
  • [Cites] J Biol Chem. 1992 Jun 25;267(18):12991-7 [1320009.001]
  • [Cites] Biochem Biophys Res Commun. 1994 May 16;200(3):1271-6 [8185575.001]
  • (PMID = 19710510.001).
  • [ISSN] 1529-7268
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD033039-12; United States / NICHD NIH HHS / HD / HD033039-11; United States / NICHD NIH HHS / HD / R01 HD033039; United States / NICHD NIH HHS / HD / R01 HD033039-13; United States / NICHD NIH HHS / HD / HD033039-13; United States / NICHD NIH HHS / HD / U54 HD028934; United States / NICHD NIH HHS / HD / R01 HD033039-11; United States / NICHD NIH HHS / HD / U54-HD28934; United States / NICHD NIH HHS / HD / HD033039-12; United States / NICHD NIH HHS / HD / HD-33039
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Anthracenes; 0 / Early Growth Response Protein 1; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Luteinizing Hormone, beta Subunit; 0 / Neoplasm Proteins; 0 / Pyridines; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / SB 203580; 0 / anthra(1,9-cd)pyrazol-6(2H)-one; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1
  • [Other-IDs] NLM/ NIHMS145990; NLM/ PMC2788048
  •  go-up   go-down


28. Visigalli D, Palmieri D, Strangio A, Astigiano S, Barbieri O, Casartelli G, Zicca A, Manduca P: The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts. BMC Cancer; 2009;9:59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We used a model of xenografts in BalbC/nude mice obtaining tumors by implanting in contro-lateral subcutaneous positions MDA MB231 cells added or not with purified PICP and studied the earlier phases of tumor development, up to 48 days from implant, by histology, immunostain and in situ hybridization.
  • RESULTS: Addition of PICP promotes rapid vascularization of the tumors while does not affect mitotic and apoptotic indexes and overall tumor growth.
  • PICP-treated, relative to control tumors, show up-modulation of Vascular endothelial factor, Metalloproteinase-9 and CXCR4, all tumor prognostic genes; they also show down-modulation of the endogenous Metalloproteinase inhibitor, reversion-inducing-cysteine-rich protein with kazal motifs, and a different pattern of modulation of Tissue Inhibitor of Metalloproteinase-2.
  • PICP may be play a relevant role in the productive interactions between stroma and tumor cells by predisposing the tumor cells to respond to the proliferation stimuli ensuing the activation of signaling by engagement of CXCR4 by cytokines and by fostering their extravasion, due to the induction of increased vascular development.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Peptide Fragments / pharmacology. Procollagen / pharmacology
  • [MeSH-minor] Animals. Chemokine CXCL12 / biosynthesis. Chemokine CXCL12 / genetics. Female. Gene Expression / drug effects. Humans. In Situ Hybridization. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 9 / biosynthesis. Matrix Metalloproteinase 9 / genetics. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Metastasis. Neovascularization, Pathologic / enzymology. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, CXCR4 / biosynthesis. Receptors, CXCR4 / genetics. Transplantation, Heterologous. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Diagn. 1999 Sep;4(3):169-83 [10553018.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32658-63 [10924500.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Breast Cancer Res Treat. 2002 Mar;72(1):69-77 [12000221.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3639-47 [12441353.001]
  • [Cites] Cell. 2003 Jul 25;114(2):171-80 [12887919.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5230-3 [14500350.001]
  • [Cites] Eur J Cell Biol. 2003 Nov;82(11):539-48 [14703010.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Anal Biochem. 1993 Nov 15;215(1):86-9 [7507651.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5517-20 [9407961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13221-6 [9789069.001]
  • [Cites] J Pathol. 1998 Nov;186(3):262-8 [10211114.001]
  • [Cites] J Cell Sci. 2008 Oct 15;121(Pt 20):3487-95 [18843117.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1237-41 [10225966.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Oncogene. 2005 Sep 1;24(38):5850-7 [16007210.001]
  • [Cites] Breast. 2005 Oct;14(5):360-7 [16216737.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):35-43 [16680570.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):30-41 [16046252.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):283-90 [16924371.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2026-9 [16671092.001]
  • [Cites] Cancer Lett. 2007 Aug 8;253(1):34-42 [17306924.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(11):1987-94 [17719831.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1659-65 [17725805.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Sep;8(3):279-87 [17447144.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):57-66 [18058195.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2050-6 [18172859.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):241-2 [18371356.001]
  • [Cites] Hum Pathol. 2008 May;39(5):731-9 [18329693.001]
  • [Cites] Exp Cell Res. 2008 Jul 1;314(11-12):2289-98 [18570923.001]
  • (PMID = 19226458.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Peptide Fragments; 0 / Procollagen; 0 / RNA, Messenger; 0 / Receptors, CXCR4; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / procollagen type I carboxy terminal peptide; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2652491
  •  go-up   go-down


29. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA, Committee of the National Cancer Research Institute: Guidelines for the welfare and use of animals in cancer research. Br J Cancer; 2010 May 25;102(11):1555-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Animal Experimentation / standards. Animal Welfare / standards. Neoplasms / pathology. Neoplasms / therapy. Practice Guidelines as Topic
  • [MeSH-minor] Algorithms. Animals. Biomarkers, Pharmacological / analysis. Biomedical Research / ethics. Biomedical Research / legislation & jurisprudence. Biomedical Research / organization & administration. Biomedical Research / standards. Cell Line, Transformed. Diagnostic Imaging. Disease Models, Animal. Female. Humans. Male. Mice. Neoplasm Transplantation / methods. Neoplasm Transplantation / pathology. Neoplasm Transplantation / standards. Treatment Outcome. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 1999 Feb;10(2):229-33 [10211554.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Nat Genet. 1999 May;22(1):37-43 [10319859.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S52-5 [10357559.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):235-46 [10359143.001]
  • [Cites] Mol Cell. 1999 May;3(5):565-77 [10360173.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):175-84 [10389994.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):645-58 [17687385.001]
  • [Cites] Peptides. 2007 Sep;28(9):1896-901 [17544169.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Anal Chem. 2007 Nov 1;79(21):8312-5 [17910417.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):1-4 [17960586.001]
  • [Cites] Cell Biol Toxicol. 2007 Nov;23(6):367-72 [17522957.001]
  • [Cites] Microcirculation. 2008 Jan;15(1):65-79 [17952797.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):94-107 [18202697.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):304-10 [18240927.001]
  • [Cites] Mol Imaging. 2004 Jul;3(3):149-58 [15530250.001]
  • [Cites] J Pediatr Surg. 2007 Jul;42(7):1172-9 [17618876.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4201-8 [17634549.001]
  • [Cites] Mol Pharm. 2007 Jul-Aug;4(4):498-512 [17629304.001]
  • [Cites] World J Gastroenterol. 2007 Aug 14;13(30):4131-5 [17696236.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):83-6 [11544530.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] J Immunother. 2001 Nov-Dec;24(6):472-81 [11759070.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):416-24 [11802201.001]
  • [Cites] Exp Hematol. 2002 Jan;30(1):89-96 [11823042.001]
  • [Cites] Biotechniques. 2002 Feb;32(2):432-4, 436, 438-40 [11848419.001]
  • [Cites] ILAR J. 2002;43(2):100-9 [11917161.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):493-7 [11920607.001]
  • [Cites] Curr Drug Metab. 2002 Oct;3(5):527-50 [12369896.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):809-15 [18253114.001]
  • [Cites] Eur J Med Chem. 2008 Mar;43(3):501-12 [17574307.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):580-9 [18385732.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Drug Resist Updat. 2008 Feb-Apr;11(1-2):51-60 [18165147.001]
  • [Cites] J Am Assoc Lab Anim Sci. 2008 May;47(3):8-15 [18459706.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3827-34 [18483267.001]
  • [Cites] Bioorg Med Chem. 2008 Jul 1;16(13):6611-6 [18502135.001]
  • [Cites] Br J Anaesth. 2008 Jul;101(1):121-4 [18424804.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):32-7 [18550454.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4572-83 [18628472.001]
  • [Cites] J Drug Target. 2008 Aug;16(7):626-37 [18686134.001]
  • [Cites] Curr Protoc Immunol. 2008 Aug;Chapter 20:Unit 20.9.1-20.9-10 [18729063.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):323-35 [18651209.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):337-42 [18661105.001]
  • [Cites] Curr Protoc Cytom. 2008 Jan;Appendix 3:Appendix 3C [18770641.001]
  • [Cites] Nature. 2008 Oct 2;455(7213):679-83 [18716624.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):359-62 [18678282.001]
  • [Cites] J Neurochem. 2008 Dec;107(5):1358-68 [19013850.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):143-50 [19117997.001]
  • [Cites] Clin Pharmacol Ther. 2009 Feb;85(2):217-21 [19005462.001]
  • [Cites] J Pharm Sci. 2009 Mar;98(3):861-93 [18683876.001]
  • [Cites] Neuroimage. 2009 Apr 1;45(2):360-9 [19154791.001]
  • [Cites] Clin Exp Metastasis. 2009;26(4):329-44 [19190882.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):274-84 [19308067.001]
  • [Cites] Toxicol Pathol. 2009 Feb;37(2):227-34 [19181629.001]
  • [Cites] Genes Dev. 2009 Apr 1;23(7):877-89 [19339691.001]
  • [Cites] PLoS One. 2009;4(4):e4992 [19352430.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]
  • [Cites] Gastroenterology. 2009 May;136(5):1514-25.e2 [19208341.001]
  • [Cites] Histol Histopathol. 2009 Jul;24(7):879-91 [19475534.001]
  • [Cites] FASEB J. 2009 Aug;23(8):2662-72 [19325038.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Aug;2(8):743-50 [19638489.001]
  • [Cites] In Vivo. 2009 Sep-Oct;23(5):661-8 [19779098.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16375-80 [19805307.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8256-64 [19843858.001]
  • [Cites] Oncogene. 2009 Nov 12;28(45):4009-21 [19718054.001]
  • [Cites] J Nutr. 2009 Dec;139(12):2373-9 [19864400.001]
  • [Cites] Am J Bioeth. 2009 Dec;9(12):55-9 [20013503.001]
  • [Cites] Carcinogenesis. 2009 Dec;30(12):2100-8 [19808857.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):59-64 [20029424.001]
  • [Cites] Anticancer Res. 2009 Nov;29(11):4389-95 [20032383.001]
  • [Cites] Radiat Res. 2010 Jan;173(1):10-20 [20041755.001]
  • [Cites] Dis Model Mech. 2010 Jan-Feb;3(1-2):111-9 [20007486.001]
  • [Cites] Mol Cancer Ther. 2010 Feb;9(2):257-67 [20124458.001]
  • [Cites] Nature. 2010 Feb 18;463(7283):893-8 [20164919.001]
  • [Cites] Clin Cancer Res. 2010 Mar 1;16(5):1442-51 [20179238.001]
  • [Cites] Comb Chem High Throughput Screen. 2010 Feb;13(2):170-87 [20053162.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):640-4 [9679770.001]
  • [Cites] In Vivo. 1998 Jul-Aug;12(4):403-10 [9706492.001]
  • [Cites] J Immunol Methods. 1994 Jun 24;172(2):209-17 [7518484.001]
  • [Cites] J Laser Appl. 1993 Fall;5(2-3):43-60 [10146408.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):836-9 [7531615.001]
  • [Cites] Invasion Metastasis. 1994-1995;14(1-6):349-61 [7657528.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2702-7 [8610104.001]
  • [Cites] Br J Haematol. 1996 May;93(2):412-20 [8639441.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S232-5 [8763887.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(1):45-56 [8738605.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):2985-95 [9214616.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] Science. 1997 Oct 3;278(5335):120-3 [9311916.001]
  • [Cites] Drug Metab Rev. 1997 Nov;29(4):891-922 [9421679.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):843-8 [9615730.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1599-609 [9620848.001]
  • [Cites] Lab Anim Sci. 1999 Jun;49(3):319-23 [10403450.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1801-8 [10469627.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):294-7 [15549090.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8651-6 [15574773.001]
  • [Cites] Stat Med. 2005 Jan 15;24(1):109-19 [15523707.001]
  • [Cites] Pediatr Res. 2005 Jan;57(1):67-75 [15557109.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Methods Mol Med. 2005;111:323-34 [15911988.001]
  • [Cites] J Neurooncol. 2005 May;73(1):29-36 [15933813.001]
  • [Cites] World J Gastroenterol. 2005 Jun 14;11(22):3335-8 [15948235.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):241-6 [15936723.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):718-26 [15924142.001]
  • [Cites] Nat Biotechnol. 2005 Jul;23(7):790; author reply 791 [16003354.001]
  • [Cites] Altern Lab Anim. 2005 Apr;33(2):119-27 [16180987.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):796-806 [16195751.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7023-32 [16203796.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7104s-7108s [16203809.001]
  • [Cites] J Neurosci Methods. 2005 Oct 30;148(2):154-60 [15964078.001]
  • [Cites] Magn Reson Imaging. 2005 Nov;23(9):961-6 [16310112.001]
  • [Cites] Haematologica. 2006 Feb;91(2):176-83 [16461301.001]
  • [Cites] Clin Exp Metastasis. 2005;22(7):549-58 [16475025.001]
  • [Cites] Curr Drug Metab. 2006 Feb;7(2):165-82 [16472106.001]
  • [Cites] Kobe J Med Sci. 2005;51(5-6):67-72 [16501317.001]
  • [Cites] J Microbiol. 2006 Feb;44(1):42-9 [16554716.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3351-4, discussion 3354 [16585151.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9 [16585152.001]
  • [Cites] Lab Anim. 2006 Apr;40(2):111-4 [16600070.001]
  • [Cites] Cancer Sci. 2006 May;97(5):355-61 [16630131.001]
  • [Cites] Hum Cell. 2006 Feb;19(1):43-8 [16643607.001]
  • [Cites] J Natl Cancer Inst. 2006 May 3;98(9):580-98 [16670384.001]
  • [Cites] J Chem Inf Model. 2006 May-Jun;46(3):1379-87 [16711757.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1496-510 [16705038.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2006 Mar-Apr;42(3-4):63-9 [16759150.001]
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):97-104 [16624384.001]
  • [Cites] J Med Chem. 2006 Jun 29;49(13):3948-54 [16789751.001]
  • [Cites] Eur J Haematol. 2006 Aug;77(2):128-33 [16856908.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4429-40 [16547501.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):739-41 [16915261.001]
  • [Cites] Hepatology. 2006 Sep;44(3):602-11 [16941710.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 6;98(17):1176-8 [16954466.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):741-54 [16915232.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):621-81 [16968952.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):214-7 [16957739.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] Lasers Med Sci. 2006 Dec;21(4):198-201 [16964439.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):428-40 [17308044.001]
  • [Cites] Mol Imaging Biol. 2007 Mar-Apr;9(2):78-82 [17285239.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2168-77 [17404101.001]
  • [Cites] Gut. 1999 Dec;45(6):812-7 [10562577.001]
  • [Cites] Eur J Cancer. 1999 Aug;35(8):1286-91 [10615243.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1207-11 [10622530.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Ann N Y Acad Sci. 1999;889:45-51 [10668481.001]
  • [Cites] Clin Diagn Lab Immunol. 2000 Mar;7(2):141-4 [10702484.001]
  • [Cites] J Epidemiol. 1999 Dec;9(6 Suppl):S58-65 [10709351.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2995-3001 [10898343.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3605-11 [10910075.001]
  • [Cites] Neoplasia. 1999 Apr;1(1):50-62 [10935470.001]
  • [Cites] Nature. 2000 Aug 10;406(6796):641-5 [10949306.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Lab Anim. 2001 Jan;35(1):1-41 [11201285.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):513-6 [11212243.001]
  • [Cites] J Appl Toxicol. 2001 Jan-Feb;21(1):15-23 [11180276.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):27-43 [11259831.001]
  • [Cites] Exp Hematol. 2001 Mar;29(3):322-9 [11274760.001]
  • [Cites] Comb Chem High Throughput Screen. 2001 May;4(3):245-63 [11375740.001]
  • [Cites] Nat Med. 2001 Jul;7(7):864-8 [11433354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7 [11416159.001]
  • [Cites] Contemp Top Lab Anim Sci. 2000 Jul;39(4):24-7 [11487225.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6297-302 [11507085.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(16):2128-36 [12387838.001]
  • [Cites] ILAR J. 2002;43(4):191-3 [12391393.001]
  • [Cites] ILAR J. 2002;43(4):244-58 [12391400.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15608-13 [12438689.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):43-52 [12497205.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):305-11 [12527927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4239-43 [12874032.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2831-42 [12807936.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4952-9 [12941820.001]
  • [Cites] Inhal Toxicol. 2003 Sep 15;15(11):1133-43 [12955618.001]
  • [Cites] J Vet Sci. 2001 Apr;2(1):53-8 [14614295.001]
  • [Cites] Carcinogenesis. 2003 Dec;24(12):1887-96 [12949047.001]
  • [Cites] Can J Neurol Sci. 2003 Nov;30(4):326-32 [14672264.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):821-5 [14729596.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):821-6 [15120037.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):827-36 [15120038.001]
  • [Cites] Immunol Res. 2004;29(1-3):269-82 [15181288.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):539-51 [15193257.001]
  • [Cites] Lab Anim. 2004 Jul;38(3):286-96 [15207040.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5624-31 [15313900.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6537-41 [15374965.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Oct;19(10):1192-8 [15377299.001]
  • [Cites] Cancer Immunol Immunother. 2004 Nov;53(11):946-54 [15185012.001]
  • [Cites] Cancer Chemother Rep. 1966 May;50(4):219-44 [4957125.001]
  • [Cites] Endocrinology. 1968 May;82(5):1049-52 [5653116.001]
  • [Cites] Cell. 1987 May 22;49(4):465-75 [3032456.001]
  • [Cites] Radiat Res. 1987 Dec;112(3):581-91 [3321144.001]
  • [Cites] Lab Anim. 1988 Jul;22(3):195-201 [3172698.001]
  • [Cites] J Natl Cancer Inst. 1991 May 1;83(9):627-32 [1708835.001]
  • [Cites] Urol Res. 1991;19(4):207-13 [1926654.001]
  • [Cites] Lab Anim Sci. 1991 Jun;41(3):269-73 [1658469.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(3):473-6 [1735681.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5395-9 [1394144.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1055-62 [7692730.001]
  • [Cites] Br J Cancer. 1993 Nov;68(5):909-15 [8217606.001]
  • [CommentIn] Br J Cancer. 2010 May 25;102(11):1553-4 [20502459.001]
  • (PMID = 20502460.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10337; United Kingdom / Cancer Research UK / / 10345; United Kingdom / Cancer Research UK / / 9993; United Kingdom / Medical Research Council / / G0500366; United Kingdom / National Centre for the Replacement, Refinement and Reduction of Animals in Research / / G1000121/1
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Pharmacological
  • [Other-IDs] NLM/ PMC2883160
  •  go-up   go-down


30. Brown HM, Wilkinson EJ: Cytology of secondary vulvar Paget's disease of urothelial origin: a case report. Acta Cytol; 2005 Jan-Feb;49(1):71-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of secondary vulvar Paget's disease of urothelial origin: a case report.
  • BACKGROUND: Primary cutaneous Paget's disease of the vulva is an intraepithelial adenocarcinoma most likely arising from a cutaneous stem cell with sweat gland epithelial differentiation or can be of sweat gland origin.
  • Primary vulvar Paget's disease, however, can be mimicked by an internal noncutaneous neoplasm htat has extended to secondarily involve the vulva.
  • Most commonly, this is due to an anal or rectal adenocarcinoma or a urothelial carcinoma.
  • CASE: An 81-year-old woman with a past history of urothelial carcinoma in situ of the bladder presented severalyears subsequent to treatment for bladder cancer with extensive vulvar and vaginal disease, clinically interpreted as primary vulvar Paget's disease involving the vagina.
  • Subsequent investigation of her bladder showed recurrent urothelial carcinoma in situ with extensive spread to the vagina and vulva, simulating primary cutaneous vulvar Paget's disease.
  • CONCLUSION: It is important to recognize secondary vulvar Paget's disease, although uncommon, because of the difference in therapy for primary and secondary vulvar Paget's disease.
  • Certain cytologic characteristics in a vaginal or vulvar smear in a patient with suspected vulvar Paget's disease may aid in distinguishing them.
  • [MeSH-major] Paget Disease, Extramammary / pathology. Paget Disease, Extramammary / secondary. Urothelium / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma / pathology. Female. Humans. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717759.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Kim JB, Urban K, Cochran E, Lee S, Ang A, Rice B, Bata A, Campbell K, Coffee R, Gorodinsky A, Lu Z, Zhou H, Kishimoto TK, Lassota P: Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS One; 2010;5(2):e9364
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early detection of tumors can significantly improve the outcome of tumor treatment.
  • The resulting single cell clones of the mouse mammary gland tumor (4T1-luc2) showed stable light emission in the range of 10,000 photons/sec/cell.
  • In addition, we showed that only few cells are needed to develop tumors in these mice and tumor progression can be monitored right after the cells are implanted.
  • [MeSH-major] Diagnostic Imaging / methods. Luciferases / metabolism. Luminescent Measurements / methods. Mammary Neoplasms, Experimental / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Genetic Vectors / genetics. Lentivirus / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Neoplasms / genetics. Neoplasms / metabolism. Neoplasms / pathology. Sensitivity and Specificity. Time Factors. Transfection. Tumor Burden

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6116-24 [18829490.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14342-6 [18794521.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):5-22 [11205917.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12227-32 [11035804.001]
  • [Cites] Mol Ther. 2004 Sep;10(3):545-52 [15336654.001]
  • [Cites] Mol Ther. 2001 Mar;3(3):319-22 [11273773.001]
  • [Cites] Gene Ther. 2001 Oct;8(20):1539-46 [11704814.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 27;100(11):6706-11 [12754375.001]
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(5):826-33 [12879192.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):221-6 [14688412.001]
  • [Cites] Clin Exp Metastasis. 2003;20(8):733-44 [14713107.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Prostate. 2004 May 15;59(3):292-303 [15042605.001]
  • [Cites] Mol Imaging. 2004 Jan;3(1):9-23 [15142408.001]
  • [Cites] Nat Med. 2004 Jun;10(6):643-8 [15122251.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Nat Med. 1995 Feb;1(2):149-53 [7585012.001]
  • [Cites] Nucleic Acids Res. 1996 May 1;24(9):1787-8 [8650001.001]
  • [Cites] Nat Biotechnol. 1997 Sep;15(9):871-5 [9306402.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(3):279-84 [10352881.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1257-60 [15502845.001]
  • [Cites] Oncology. 2006;70(6):418-26 [17245103.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):024007 [17477722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Feb;134(2):137-46 [17622558.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1594-601 [18578010.001]
  • [Cites] BMC Cancer. 2008;8:228 [18691423.001]
  • [Cites] Mol Ther. 2008 Nov;16(11):1848-56 [18766175.001]
  • (PMID = 20186331.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2826408
  •  go-up   go-down


32. Radestock Y, Hoang-Vu C, Hombach-Klonisch S: Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells. Breast Cancer Res; 2008;10(4):R71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Relaxin levels are increased in cases of human breast cancer and has been shown to promote cancer cell migration in carcinoma cells of the breast, prostate gland and thyroid gland.
  • [MeSH-major] Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Relaxin / physiology
  • [MeSH-minor] Animals. Carcinoma / metabolism. Carcinoma / pathology. Cell Line, Tumor. Humans. Male. Mice. Mice, Nude. Neoplasm Metastasis. Neoplasm Transplantation. Prognosis. Receptors, Estrogen / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1999 Nov;435(5):509-19 [10592055.001]
  • [Cites] Br J Pharmacol. 2007 Mar;150(6):677-91 [17293890.001]
  • [Cites] Hum Pathol. 2000 May;31(5):593-600 [10836299.001]
  • [Cites] Mol Endocrinol. 2000 Aug;14(8):1257-71 [10935549.001]
  • [Cites] Biochim Biophys Acta. 2000 Dec 20;1498(2-3):252-63 [11108967.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22699-708 [11278647.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4685-95 [11498791.001]
  • [Cites] Science. 2002 Jan 25;295(5555):671-4 [11809971.001]
  • [Cites] Mol Hum Reprod. 2002 Sep;8(9):789-96 [12200455.001]
  • [Cites] Biol Reprod. 2002 Dec;67(6):1919-26 [12444070.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):7855-62 [12506116.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3683-91 [12865351.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):30063-73 [12756252.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):253-62 [14710237.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):205-34 [15082520.001]
  • [Cites] Hum Reprod. 2004 Jul;19(7):1513-8 [15155604.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(2):157-66 [15377840.001]
  • [Cites] Anal Biochem. 1979 Apr 1;94(1):96-9 [88913.001]
  • [Cites] Endocr Rev. 1982 Winter;3(1):62-90 [6277610.001]
  • [Cites] Lancet. 1990 Feb 3;335(8684):298-9 [1967759.001]
  • [Cites] Clin Exp Obstet Gynecol. 1991;18(3):161-4 [1752047.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):639-43 [1320450.001]
  • [Cites] Gene. 1993 Dec 15;135(1-2):229-38 [8276262.001]
  • [Cites] Int J Cancer. 1994 Apr 1;57(1):129-34 [8150531.001]
  • [Cites] J Biol Chem. 1994 Jul 22;269(29):18992-9 [8034656.001]
  • [Cites] J Biol Chem. 1994 Aug 5;269(31):19679-82 [8051043.001]
  • [Cites] J Mol Endocrinol. 1994 Jun;12(3):351-64 [7916973.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1597-605 [7731714.001]
  • [Cites] Invasion Metastasis. 1994-1995;14(1-6):329-36 [7657526.001]
  • [Cites] Oncogene. 1995 Nov 16;11(10):2067-75 [7478526.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):831-41 [8824556.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1621-30 [8895507.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1631-7 [8895508.001]
  • [Cites] Int J Cancer. 1997 May 29;71(5):832-7 [9180153.001]
  • [Cites] Endocrinology. 1999 May;140(5):2426-9 [10218998.001]
  • [Cites] J Biol Chem. 2005 May 27;280(21):20833-41 [15788416.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1041:35-9 [15956685.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1041:449-61 [15956746.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1041:462-9 [15956747.001]
  • [Cites] J Dairy Res. 2005;72 Spec No:27-33 [16180718.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):62-73 [16049981.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1277-84 [16265347.001]
  • [Cites] Endocrinology. 2006 Jan;147(1):407-14 [16223865.001]
  • [Cites] Cancer Biol Ther. 2006 Jan;5(1):71-7 [16322684.001]
  • [Cites] Urology. 2007 Sep;70(3):602-7 [17688917.001]
  • [Cites] Am J Pathol. 2006 Aug;169(2):617-32 [16877360.001]
  • [Cites] Prostate. 2006 Dec 1;66(16):1698-709 [16998820.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1695-702 [17363522.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1595-603 [10749128.001]
  • (PMID = 18718015.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human; 9002-69-1 / Relaxin
  • [Other-IDs] NLM/ PMC2575545
  •  go-up   go-down


33. Richardson AD, Yang C, Osterman A, Smith JW: Central carbon metabolism in the progression of mammary carcinoma. Breast Cancer Res Treat; 2008 Jul;110(2):297-307
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is a growing belief that the metabolic program of breast tumor cells could be a therapeutic target.
  • Yet, without detailed information on central carbon metabolism in breast tumors it is impossible to know which metabolic pathways to target, and how their inhibition might influence different stages of breast tumor progression.
  • Here we perform the first comprehensive profiling of central metabolism in the MCF10 model of mammary carcinoma, where the steps of breast tumor progression (transformation, tumorigenicity and metastasis) can all be examined in the context of the same genetic background.
  • The de novo synthesis of glycine increased upon transformation as well as at each subsequent step of breast tumor cell progression.
  • Interestingly, the major metabolic shift in metastatic cells is a large increase in the de novo synthesis of proline.
  • This work provides the first comprehensive view of changes to central metabolism as a result of breast tumor progression.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2004 Aug;18(11):1303-5 [15180958.001]
  • [Cites] Pac Symp Biocomput. 2007;:181-92 [17990491.001]
  • [Cites] Nutrition. 2000 Mar;16(3):202-8 [10705076.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1088-95 [11459870.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45358-66 [11567032.001]
  • [Cites] Annu Rev Med. 2002;53:89-112 [11818465.001]
  • [Cites] J Biol Chem. 2002 Jun 28;277(26):23111-5 [11943784.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):132-7 [12531699.001]
  • [Cites] Anal Biochem. 2003 Feb 1;313(1):145-54 [12576070.001]
  • [Cites] Proteomics. 2003 Jul;3(7):1256-69 [12872226.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4459-68 [12881702.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):459-65 [14697210.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:239-67 [14744246.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2070-5 [15026345.001]
  • [Cites] J Biol Chem. 1990 Aug 15;265(23):13641-9 [2380179.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Carcinog. 1991;4(1):25-35 [2009132.001]
  • [Cites] Eye (Lond). 1992;6 ( Pt 4):416-9 [1478318.001]
  • [Cites] Am J Physiol. 1994 Mar;266(3 Pt 1):E372-83 [8166257.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4293-6 [7671238.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 1):E843-51 [9612242.001]
  • [Cites] Z Naturforsch C. 1998 Mar-Apr;53(3-4):279-85 [9618942.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):77-85 [15652751.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5512-5 [15994921.001]
  • [Cites] J Biol Chem. 2005 Jul 8;280(27):25339-49 [15851470.001]
  • [Cites] Hum Mol Genet. 2005 Aug 1;14(15):2231-9 [15987702.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):177-86 [16319984.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):358-65 [16778563.001]
  • [Cites] Sci STKE. 2006 Jul 31;2006(346):re7 [16885148.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8927-30 [16982728.001]
  • [Cites] Metab Eng. 2006 Nov;8(6):639-52 [16904360.001]
  • [Cites] J Nutr. 2004 Nov;134(11):3201S-3204S [15514307.001]
  • (PMID = 17879159.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108959; United States / NCI NIH HHS / CA / R01 CA108959; United States / NCI NIH HHS / CA / P30 CA030199; United States / NIAID NIH HHS / AI / R01 AI059146; United States / NCRR NIH HHS / RR / U54 RR020843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fatty Acids; 0 / Lactates; 7440-44-0 / Carbon; 9DLQ4CIU6V / Proline; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ PMC2440942
  •  go-up   go-down


34. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • The hedgehog pathway regulates epithelial-mesenchymal interactions, differentiation, proliferation and survival during development.
  • Stimulation of hedgehog signaling induces carcinogenesis or promotes cell survival in cancers of multiple organs.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • Hedgehog ligands were expressed at higher levels in some cancer epithelial cell lines compared to noncancerous epithelial cells.
  • Correspondingly, expression of GLI1, a transcription factor and transcriptional product of hedgehog signaling, was increased 8-fold in cancer epithelial cell lines; however, PTCH1, also a transcriptional target of hedgehog signaling in many cell types, was not increased.
  • GLI1 protein and mRNA, and PTCH1 and sonic hedgehog (SHH) proteins were elevated in 3 of 10 breast cancers; however, PTCH1 transcripts were not consistently increased.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • Treatment with sonic hedgehog ligand diminished the cyclopamine-induced reduction in GLI-dependent promoter activity in MCF10AT and MDA-MB-435 and viability of MDA-MB-435.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.
  • Determination as to whether the increase in GLI1 and SHH expression in breast cancer indicates a significant increase in hedgehog signaling will require further evaluation.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


35. Stone N, Hart Prieto MC, Crow P, Uff J, Ritchie AW: The use of Raman spectroscopy to provide an estimation of the gross biochemistry associated with urological pathologies. Anal Bioanal Chem; 2007 Mar;387(5):1657-68
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have shown for the first time that we are able to utilise Raman spectroscopy in determining the biochemical basis for the different pathologies within the bladder and prostate gland.
  • In this way we can achieve a better understanding of disease processes such as carcinogenesis.
  • This could have major implications in the future of the diagnosis of disease within the bladder and the prostate gland.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / metabolism. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Computer-Assisted / methods. Female. Humans. Male. Spectrum Analysis, Raman / methods. Urologic Neoplasms / diagnosis. Urologic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123068.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / CSA/03/07/017
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


36. Chesnokova V, Melmed S: Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):55-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular senescence is characterized by a largely irreversible cell cycle arrest and constitutes a strong anti-proliferative response, which can be triggered by DNA damage, chromosomal instability and aneuploidy, loss of tumor suppressive signaling or oncogene activation.
  • Both deletion and over-expression of pituitary tumor transforming gene (Pttg) promote chromosomal instability and aneuploidy.
  • Pttg deletion abrogates tumor development by activating p53/p21-dependent senescence pathways.
  • Pituitary p21 may therefore safeguard against further chromosomal instability by constraining pituitary tumor growth.
  • These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1729-33 [11748253.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):503-11 [11850775.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]
  • [Cites] Cell. 2003 Jun 13;113(6):703-16 [12809602.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):156-66 [9892021.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Exp Cell Res. 1961 Dec;25:585-621 [13905658.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):6-10 [15692944.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):660-5 [16079837.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Science. 2005 Aug 5;309(5736):886-7 [16081723.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] Trends Genet. 2008 Feb;24(2):77-85 [18192065.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell. 2008 Jun 13;133(6):958-61 [18555773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]
  • [Cites] Pituitary. 2009;12(1):40-50 [18270844.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):81-94 [19132009.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):677-8 [19223763.001]
  • [Cites] Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82 [19650784.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Cell. 2007 Jul 27;130(2):223-33 [17662938.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • (PMID = 20153804.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-11A1; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / R01 CA075979-11A1
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Other-IDs] NLM/ NIHMS185500; NLM/ PMC2906651
  •  go-up   go-down


37. Zagouri F, Sergentanis TN, Zografos GC: Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol; 2007;5:57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Precursors and preinvasive lesions of the breast include atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), and lobular neoplasia (LN).
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Breast Neoplasms / therapy. Neoplasm Invasiveness / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1995 Dec 15;14(24):6107-15 [8557030.001]
  • [Cites] Arch Pathol Lab Med. 1996 Jan;120(1):81-5 [8554451.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1719-23 [16033090.001]
  • [Cites] J Med Genet. 2005 Oct;42(10):763-5 [15879498.001]
  • [Cites] Adv Anat Pathol. 2005 Sep;12(5):256-64 [16210921.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1723-39 [15980158.001]
  • [Cites] Histopathology. 2005 Nov;47(5):445-57 [16241992.001]
  • [Cites] Mol Endocrinol. 2005 Nov;19(11):2713-35 [15976005.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1593-9 [16327431.001]
  • [Cites] Histopathology. 2005 Dec;47(6):617-24 [16324200.001]
  • [Cites] Saudi Med J. 2005 Dec;26(12):1889-96 [16380768.001]
  • [Cites] Cell Res. 2006 Feb;16(2):203-13 [16474435.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):681-5 [16495929.001]
  • [Cites] Breast Cancer Res. 2006;8(1):R6 [16417654.001]
  • [Cites] Am J Surg. 2006 Jul;192(1):68-71 [16769278.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1148-52 [16775174.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R22 [16613616.001]
  • [Cites] Cell. 2006 Jul 14;126(1):30-2 [16839873.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):319-23 [16924373.001]
  • [Cites] Nucl Med Commun. 2006 Nov;27(11):911-7 [17021432.001]
  • [Cites] Am J Surg Pathol. 2006 Nov;30(11):1445-53 [17063087.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):909-23 [17128209.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Sep;45(6):831-40 [10541479.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1811-5 [10595909.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2096-101 [10601380.001]
  • [Cites] J Pathol. 1999 Dec;189(4):521-6 [10629552.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):267-74 [10637239.001]
  • [Cites] Cancer. 2000 May 1;88(9):2072-81 [10813719.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):622-30 [12628841.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(2):193-204 [12725419.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(2):187-98 [12825853.001]
  • [Cites] Breast Cancer Res. 2003;5(5):254-7 [12927035.001]
  • [Cites] Breast Cancer Res. 2003;5(5):263-8 [12927037.001]
  • [Cites] Breast Cancer Res. 2003;5(5):269 [12927038.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):28-32 [14734448.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jul;5(3):271-81 [14973389.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):55-66 [15082918.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):67-80 [15082919.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2317-27 [15160334.001]
  • [Cites] Cancer Lett. 2004 Aug 20;212(1):121-30 [15246568.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1076-91 [15252316.001]
  • [Cites] Pathol Int. 2004 Aug;54(8):595-602 [15260850.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):721-40 [15361179.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):695-9 [15375487.001]
  • [Cites] J Pathol. 2004 Oct;204(2):140-6 [15376259.001]
  • [Cites] Int J Biol Markers. 2004 Jul-Sep;19(3):236-9 [15503826.001]
  • [Cites] JAMA. 1978 May 5;239(18):1863-7 [205686.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):751-8 [6275978.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):129-35 [8569175.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):499-506 [8630957.001]
  • [Cites] Pathol Res Pract. 1996 Feb;192(2):117-23 [8692711.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):1138-40 [8780555.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1403-16 [8839545.001]
  • [Cites] Breast Cancer Res Treat. 1996;41(2):103-9 [8944328.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):578-82 [9005143.001]
  • [Cites] Virchows Arch. 1997 Jan;430(1):17-22 [9037310.001]
  • [Cites] Virchows Arch. 1997 Jan;430(1):23-8 [9037311.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):39-44 [9071897.001]
  • [Cites] Histopathology. 1997 Oct;31(4):347-54 [9363451.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):37-42 [9428781.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):785-9 [9485035.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):140-54 [9504685.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):697-703 [9586667.001]
  • [Cites] Oncogene. 1998 May 28;16(21):2723-7 [9652738.001]
  • [Cites] Pathol Int. 1998 Jul;48(7):518-25 [9701014.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4721-7 [9788628.001]
  • [Cites] Clin Cancer Res. 1995 Mar;1(3):261-7 [9815981.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S53-67 [10396301.001]
  • [Cites] J Pathol. 1999 Mar;187(4):396-402 [10398097.001]
  • [Cites] J Pathol. 1999 Jul;188(3):245-51 [10419590.001]
  • [Cites] Histopathology. 1999 Sep;35(3):195-200 [10469210.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1048-58 [10478664.001]
  • [Cites] Mol Endocrinol. 1999 Oct;13(10):1657-71 [10517668.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1277-80 [10523696.001]
  • [Cites] Virchows Arch. 1999 Oct;435(4):413-21 [10526005.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):857-9 [15499614.001]
  • [Cites] Breast Cancer Res. 2004;6(2):75-81 [14979910.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):105-8 [15613861.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):414-21 [15578730.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):429-34 [15736216.001]
  • [Cites] Breast Cancer Res Treat. 2005 Apr;90(3):249-56 [15830138.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):741-51 [15696125.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):336-43 [15922292.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Methods Enzymol. 1986;134:355-71 [2434826.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5748-51 [3664479.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):246-53 [2825969.001]
  • [Cites] Br J Cancer. 1988 Oct;58(4):453-7 [2849975.001]
  • [Cites] Histopathology. 1989 Oct;15(4):351-62 [2572531.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):387-93 [2404554.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):209-21 [1847606.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):641-4 [1317202.001]
  • [Cites] Hum Pathol. 1992 Sep;23(9):974-9 [1355464.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1258-65 [8435803.001]
  • [Cites] Hum Pathol. 1993 May;24(5):463-8 [8098318.001]
  • [Cites] Jpn J Cancer Res. 1993 Apr;84(4):394-401 [8099903.001]
  • [Cites] Epidemiol Rev. 1993;15(1):17-35 [8405201.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1849-53 [7907946.001]
  • [Cites] Lab Invest. 1994 Jul;71(1):67-72 [8041120.001]
  • [Cites] Cytogenet Cell Genet. 1995;68(1-2):49-51 [7956357.001]
  • [Cites] Eur J Cancer. 1994;30A(10):1414-9 [7833094.001]
  • [Cites] Hum Pathol. 1995 Feb;26(2):155-8 [7860045.001]
  • [Cites] J Cell Sci Suppl. 1994;18:51-5 [7883792.001]
  • [Cites] Cancer Lett. 1995 Mar 23;90(1):97-102 [7720048.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3976-81 [7664266.001]
  • [Cites] J Clin Pathol. 1995 Jul;48(7):611-5 [7560165.001]
  • [Cites] Virchows Arch. 2000 May;436(5):421-30 [10881735.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4346-8 [10969774.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 31;1471(1):M43-56 [10967424.001]
  • [Cites] J Clin Pathol. 2000 Oct;53(10):778-83 [11064673.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Pathobiology. 2000 May-Jun;68(3):129-36 [11174070.001]
  • [Cites] Pathol Int. 2001 Feb;51(2):94-9 [11169147.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):42-55 [11237522.001]
  • [Cites] J Pathol. 2001 Mar;193(3):333-8 [11241412.001]
  • [Cites] Jpn J Cancer Res. 2001 Mar;92(3):302-8 [11267940.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2537-41 [11289127.001]
  • [Cites] Mol Pathol. 2001 Apr;54(2):91-7 [11322170.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):709-18 [11345835.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Exp Mol Pathol. 2001 Jun;70(3):303-16 [11418009.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3348-53 [11423985.001]
  • [Cites] Breast Cancer Res. 2001;3(4):276-83 [11434879.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):67-82 [11467453.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2410-4 [11489820.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1514-22 [11506959.001]
  • [Cites] Surgery. 2001 Oct;130(4):593-600; discussion 600-1 [11602889.001]
  • [Cites] J Mol Med (Berl). 2001 Nov;79(11):648-55 [11715068.001]
  • [Cites] Breast Cancer Res. 2001;3(6):385-9 [11737890.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):597-604 [11839580.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):116-24 [11850540.001]
  • [Cites] J Pathol. 2002 Mar;196(3):280-6 [11857490.001]
  • [Cites] Breast Cancer Res. 2002;4(2):70-6 [11879567.001]
  • [Cites] Arch Pathol Lab Med. 2002 Apr;126(4):456-8 [11900572.001]
  • [Cites] J Clin Pathol. 2002 Jun;55(6):461-6 [12037031.001]
  • [Cites] Breast Cancer Res Treat. 2002 Mar;72(2):163-72 [12038707.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):620-7 [12152161.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1081-6 [12168077.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1909-11 [12168892.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1341-5 [12168948.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1044-50 [12379750.001]
  • [Cites] J Pathol. 2002 Dec;198(4):458-67 [12434415.001]
  • [Cites] Anal Cell Pathol. 2002;24(2-3):69-76 [12446956.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):125-9 [12531579.001]
  • [Cites] Breast Cancer Res. 2003;5(6):309-12 [14580248.001]
  • [Cites] Breast Cancer Res. 2003;5(6):313-9 [14580249.001]
  • [Cites] Breast Cancer Res. 2003;5(6):320-8 [14580250.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1502-12 [14657709.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):182-8 [14710227.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Mar;39(3):236-48 [14732925.001]
  • (PMID = 17540032.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 161
  • [Other-IDs] NLM/ PMC1894800
  • [General-notes] NLM/ Original DateCompleted: 20070813
  •  go-up   go-down


38. van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE: Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer; 2006;6:86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.
  • BACKGROUND: Sensitivity of breast tumors to anticancer drugs depends upon dynamic interactions between epithelial tumor cells and their microenvironment including stromal cells and extracellular matrix.
  • To study drug-sensitivity within different compartments of an individual tumor ex vivo, culture models directly established from fresh tumor tissues are absolutely essential.
  • METHODS: We prepared 0.2 mm thick tissue slices from freshly excised tumor samples and cultivated them individually in the presence or absence of taxol for 4 days.
  • RESULTS: We obtained a mean of 49 tissue slices from 22 breast cancer specimens allowing a wide range of experiments in each individual tumor.
  • A three-color fluorescence viability assay enabled a rapid and authentic estimation of cell viability in the different tumor compartments within non-fixed tissue slices.
  • This method has potential significance for studying tumor responses to anticancer drugs in the complex environment of a primary cancer tissue.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Drug Screening Assays, Antitumor / methods. Paclitaxel / pharmacology
  • [MeSH-minor] Adenosine Triphosphate / analysis. Apoptosis / drug effects. Cell Division / drug effects. Cell Survival. DNA, Neoplasm / analysis. Female. Humans. Microscopy, Confocal. Microscopy, Fluorescence. Tumor Cells, Cultured / chemistry. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1998;194(3):177-81 [9587936.001]
  • [Cites] Physiol Rev. 1996 Jan;76(1):69-125 [8592733.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Apr;4(2):193-201 [10426398.001]
  • [Cites] Mol Cell Neurosci. 2005 Jan;28(1):42-54 [15607940.001]
  • [Cites] Toxicol Sci. 2005 Feb;83(2):257-63 [15525692.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):627-36 [15818402.001]
  • [Cites] Methods Mol Med. 2005;110:101-20 [15901931.001]
  • [Cites] Biotechnol Prog. 2005 Jul-Aug;21(4):1289-96 [16080713.001]
  • [Cites] Endocr Relat Cancer. 2000 Jun;7(2):95-113 [10903527.001]
  • [Cites] Breast Cancer Res. 2001;3(4):218-23 [11434872.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):186-94 [11774263.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):205-16 [12242153.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] Breast Cancer Res. 2003;5(2):89-95 [12631387.001]
  • [Cites] J Cell Sci. 2003 Jun 15;116(Pt 12):2377-88 [12766184.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):169-72 [12962682.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1789-95 [14583785.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1751-6 [14996736.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jun;85(3):281-91 [15111767.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):85-90 [15201964.001]
  • [Cites] Neoplasma. 1967;14(5):507-19 [5583355.001]
  • [Cites] Anal Biochem. 1980 May 1;104(1):118-23 [6770714.001]
  • [Cites] Biomed Biochim Acta. 1983;42(7-8):907-16 [6316948.001]
  • [Cites] Ann N Y Acad Sci. 1986;464:58-65 [2942075.001]
  • [Cites] Cancer Drug Deliv. 1987;4(2):63-74 [3427553.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):78-83 [2293560.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • (PMID = 16603054.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 8L70Q75FXE / Adenosine Triphosphate; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1456977
  •  go-up   go-down


39. Huang C, Liang X, Huang R, Zhang Z: Up-regulation and clinical relevance of novel helicase homologue DHX32 in colorectal cancer. J Exp Clin Cancer Res; 2009;28:11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differentially expressed genes were confirmed by real-time PCR and then their clinical relevance (such as association with tumor location and lymph gland metastasis) was further investigated.
  • In addition, we found that the level of DHX32 gene expression in colorectal cancer was significantly associated with cancer location, lymph gland metastasis, cancer nodal status, differentiation grade, and Dukes, stage.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / enzymology. DEAD-box RNA Helicases / biosynthesis
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2001 Apr 10;165(1):71-9 [11248421.001]
  • [Cites] J Surg Res. 2008 Dec;150(2):212-8 [18316097.001]
  • [Cites] Mol Cell. 2001 Aug;8(2):251-62 [11545728.001]
  • [Cites] Carcinogenesis. 2001 Dec;22(12):1965-70 [11751426.001]
  • [Cites] Oncogene. 2001 Nov 22;20(53):7734-43 [11753651.001]
  • [Cites] Anal Biochem. 2002 Mar 1;302(1):52-9 [11846375.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17743-50 [11886864.001]
  • [Cites] Leuk Res. 2002 Oct;26(10):945-54 [12163057.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):185-93 [12455032.001]
  • [Cites] Gene. 2003 Jan 2;302(1-2):139-46 [12527204.001]
  • [Cites] J Biomed Sci. 2003 Nov-Dec;10(6 Pt 2):792-804 [14631119.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 6;1704(1):37-46 [15238243.001]
  • [Cites] Science. 1992 Aug 14;257(5072):967-71 [1354393.001]
  • [Cites] Nucleic Acids Res. 1992 Oct 11;20(19):4965-70 [1383934.001]
  • [Cites] Science. 1993 Feb 12;259(5097):946-51 [8438152.001]
  • [Cites] Nat Genet. 1992 Nov;2(3):173-9 [1345164.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Hematol Oncol Clin North Am. 1997 Aug;11(4):609-33 [9257148.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jan;31(1):87-106 [10216946.001]
  • [Cites] Trends Biochem Sci. 1999 May;24(5):192-8 [10322435.001]
  • [Cites] Exp Mol Pathol. 2005 Dec;79(3):219-23 [16181624.001]
  • [Cites] Clin Transl Oncol. 2006 Jun;8(6):391-8 [16790391.001]
  • [Cites] J Cell Physiol. 2007 Mar;210(3):740-9 [17133351.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):165-70 [17293392.001]
  • [Cites] Dis Colon Rectum. 2007 Aug;50(8):1188-203 [17436048.001]
  • [Cites] Nat Genet. 2008 May;40(5):600-8 [18372904.001]
  • [Cites] Exp Mol Pathol. 2008 Aug;85(1):64-7 [18482722.001]
  • [Cites] Oncogene. 2001 Jan 18;20(3):336-45 [11313963.001]
  • (PMID = 19161603.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.6.1.- / DHX32 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Other-IDs] NLM/ PMC2642774
  •  go-up   go-down


40. Vaidya KS, Harihar S, Phadke PA, Stafford LJ, Hurst DR, Hicks DG, Casey G, DeWald DB, Welch DR: Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem; 2008 Oct 17;283(42):28354-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • That metastatic tumor cells grow in selective non-native environments suggests an ability to differentially respond to local microenvironments.
  • BRMS1, like other metastasis suppressors, halts ectopic growth (metastasis) without blocking orthotopic tumor formation.
  • BRMS1-expressing tumor cells reach secondary sites but do not colonize distant tissues, compelling the hypothesis that BRMS1 selectively restricts the ability of tumor cells to respond to exogenous regulators in different tissues.
  • Specific modulation of signaling responses received from the microenvironment may ultimately dictate which environments are permissive/restrictive for tumor cell growth and provide insights into the biology underlying metastasis.

  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sci STKE. 2002 Sep 17;2002(150):re13 [12237449.001]
  • [Cites] Annu Rev Biochem. 2001;70:281-312 [11395409.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39413-21 [12888567.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1562-9 [14581478.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Chem Biol. 2004 May;11(5):619-37 [15157873.001]
  • [Cites] Am J Surg Pathol. 1978 Sep;2(3):225-51 [210682.001]
  • [Cites] Nucleic Acids Res. 1987 Aug 11;15(15):5963-71 [3627975.001]
  • [Cites] Clin Exp Metastasis. 1997 May;15(3):272-306 [9174129.001]
  • [Cites] Oncogene. 1999 Aug 19;18(33):4756-66 [10467423.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):713-7 [15705865.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3586-95 [15867352.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2764-9 [10850410.001]
  • [Cites] Clin Exp Metastasis. 2000;18(8):683-93 [11827072.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):668-77 [15818404.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):305-11 [16012707.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1307-19 [16537651.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):8683-96 [17000776.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6702-8 [17121889.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1338-45 [17322919.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1742-57 [17512859.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1006-13 [17459054.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):175-90 [17587154.001]
  • [Cites] Am J Pathol. 2008 Mar;172(3):809-17 [18276787.001]
  • [Cites] J Biol Chem. 2008 Mar 21;283(12):7438-44 [18211900.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Int J Mol Med. 2003 Jan;11(1):49-55 [12469217.001]
  • (PMID = 18664570.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / F32CA113037; United States / NCI NIH HHS / CA / R01-CA87728; United States / NCI NIH HHS / CA / CA113037-03; United States / NCI NIH HHS / CA / F32 CA113037-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRMS1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / Mitogens; 0 / Neoplasm Proteins; 0 / Phosphatidylinositol 4,5-Diphosphate; 0 / Receptors, Growth Factor; 0 / Repressor Proteins; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2661398
  •  go-up   go-down


41. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR: Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog; 2006 Aug;45(8):613-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to better understand basic mechanisms of tumor development and identify potential new biomarkers, we have performed difference gel electrophoresis (DIGE) and peptide mass fingerprinting on pooled protein extracts from patients with papillary thyroid carcinoma (PTC) compared with matched normal thyroid tissue.
  • We confirmed S100A6 as a potentially useful biomarker using immunohistochemical analysis (85% sensitivity and 69% specificity for distinguishing benign from malignant thyroid neoplasms).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Mar;56(3):281-90 [11940037.001]
  • [Cites] Proteomics. 2002 Jun;2(6):706-12 [12112852.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5056-68 [12140756.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1777-80 [12168868.001]
  • [Cites] Cancer. 1977 Jul;40(1):284-300 [880557.001]
  • [Cites] Endocrinologie. 1979 Oct-Dec;17(4):233-9 [392693.001]
  • [Cites] Anal Biochem. 1984 Apr;138(1):141-3 [6731838.001]
  • [Cites] J Biol Chem. 1991 Oct 25;266(30):20198-204 [1939080.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Dec;75(6):1398-400 [1464638.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] J Chromatogr B Biomed Appl. 1995 May 5;667(1):153-60 [7663678.001]
  • [Cites] Int J Cancer. 1996 May 16;66(4):420-6 [8635854.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3112-7 [8674069.001]
  • [Cites] Hum Pathol. 1996 Jul;27(7):633-6 [8698304.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3634-7 [8705997.001]
  • [Cites] Biochim Biophys Acta. 1996 Aug 23;1316(3):203-9 [8781539.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):325-32 [8903474.001]
  • [Cites] Electrophoresis. 1997 Oct;18(11):2071-7 [9420172.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):297-306 [9445411.001]
  • [Cites] Semin Surg Oncol. 1999 Jan-Feb;16(1):34-41 [9890738.001]
  • [Cites] Electrophoresis. 1998 Dec;19(18):3213-6 [9932817.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):683-97 [15528267.001]
  • [Cites] Histopathology. 2005 May;46(5):569-75 [15842639.001]
  • [Cites] Bioessays. 2002 Aug;24(8):749-57 [12210536.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):199-205 [12716134.001]
  • [Cites] J Clin Pathol. 2003 Jun;56(6):401-5 [12783963.001]
  • [Cites] Proteomics. 2003 Jul;3(7):1162-71 [12872217.001]
  • [Cites] Thyroid. 2003 Jul;13(7):613-20 [12964965.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):994-1005 [14764826.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):517-9 [14870775.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Proteomics. 2004 Mar;4(3):793-811 [14997500.001]
  • [Cites] FASEB J. 2004 Mar;18(3):560-1 [14715705.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2035-43 [15041723.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1600-5 [15083192.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Mol Cell Proteomics. 2004 Jun;3(6):531-3 [15075378.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4069-77 [15205313.001]
  • [Cites] Mult Scler. 2004 Jun;10(3):245-60 [15222687.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2776-88 [15352251.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4264-6 [15356019.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):960-9 [15238602.001]
  • [Cites] Arch Pathol. 1967 Dec;84(6):601-14 [6054261.001]
  • [Cites] Cancer. 1971 Sep;28(3):763-74 [5096937.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(19):6067-73 [10998068.001]
  • [Cites] Adv Clin Path. 2000 Oct;4(4):155-8 [11436147.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4920-5 [11600563.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Apr;1(3):173-81 [11705003.001]
  • (PMID = 16788983.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100560; United States / NCI NIH HHS / CA / P30 CA046934; United States / NCI NIH HHS / CA / R01 CA100560; United States / NCI NIH HHS / CA / P30 CA46934-15; United States / NIDDK NIH HHS / DK / R01 DK054383; United States / NIDDK NIH HHS / DK / DK054383
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / S100 Proteins; 105504-00-5 / S100A6 protein, human
  • [Other-IDs] NLM/ NIHMS20526; NLM/ PMC1899163
  •  go-up   go-down






Advertisement